

=> fil cap
 FILE 'CAPLUS' ENTERED AT 15:02:15 ON 25 FEB 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Feb 2009 VOL 150 ISS 9
 FILE LAST UPDATED: 24 Feb 2009 (20090224/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:


<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que 14

L1

STR



Ak @18

O~Ak
@19 20

S~Ak
@21 22

Cb @2

Hy @26

Page 1-A

5

Page 1-B
 VAR G1=H/X/18/19/21/PH/23/25/26
 NODE ATTRIBUTES:

CONNECT IS E2 RC AT 1
CONNECT IS E2 RC AT 7
CONNECT IS E1 RC AT 18
CONNECT IS E1 RC AT 20
CONNECT IS E1 RC AT 22
CONNECT IS E1 RC AT 25
CONNECT IS E1 RC AT 26
DEFAULT MLEVEL IS ATOM
GGCAT IS SAT AT 18
GGCAT IS SAT AT 20
GGCAT IS SAT AT 22
GGCAT IS MCY SAT AT 25
GGCAT IS MCY AT 26
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 11
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE

L3 552 SEA FILE=REGISTRY SSS FUL L1
L4 17 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L3

=> fil wpix

FILE 'WPIX' ENTERED AT 15:02:19 ON 25 FEB 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE LAST UPDATED: 22 FEB 2009 <20090222/UP>
MOST RECENT UPDATE: 200912 <200912/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.3 million chemical structures in DCR <<<

>>> IPC and US National Classifications have been updated
with reclassifications to the end of 2008.
ECLA classifications are complete to the end of 2008 and
F-Term and FI-Term classifications to the end of 2007.
No update date (UP) has been created for the reclassified
documents, but they can be identified by
specific update codes (see HELP CLA for details)<<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.com/stn_guide.html


FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/>

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/DWPIAnaVist2_0608.html

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

=> d que 17

L1 STR



Page 1-A

5

Page 1-B

VAR G1=H/X/18/19/21/PH/23/25/26

NODE ATTRIBUTES:

```

CONNECT IS E2 RC AT 1
CONNECT IS E2 RC AT 7
CONNECT IS E1 RC AT 18
CONNECT IS E1 RC AT 20
CONNECT IS E1 RC AT 22
CONNECT IS E1 RC AT 25
CONNECT IS E1 RC AT 26
DEFAULT MLEVEL IS ATOM
GGCAT IS SAT AT 18
GGCAT IS SAT AT 20
GGCAT IS SAT AT 22
GGCAT IS MCY SAT AT 25
GGCAT IS MCY AT 26
DEFAULT ECLEVEL IS LIMITED

```

GRAPH ATTRIBUTES:

```

RSPEC 11
NUMBER OF NODES IS 26

```

STEREO ATTRIBUTES: NONE

```

L6          99 SEA FILE=WPIX SSS FUL L1
L7          6 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L6/DCR

```

=> dup rem l4 l7

FILE 'CAPLUS' ENTERED AT 15:02:24 ON 25 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 15:02:24 ON 25 FEB 2009

COPYRIGHT (C) 2009 THOMSON REUTERS

PROCESSING COMPLETED FOR L4

PROCESSING COMPLETED FOR L7

L8 17 DUP REM L4 L7 (6 DUPLICATES REMOVED)
ANSWERS '1-17' FROM FILE CAPLUS

=> d l8 ibib abs hitstr tot


L8 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2008:1477306 CAPLUS [Full-text](#)
DOCUMENT NUMBER: 150:35382
TITLE: Pyrazolopyrimidinamine compounds as selective inhibitors for cyclin-dependent kinases and their preparation, pharmaceutical compositions and use in the treatment of CDK-mediated diseases
INVENTOR(S): Jogalekar, Ashutosh S.; Snyder, James P.; Liotta, Dennis C.; Barrett, Anthony G. M.; Coombes, Rcds; Ali, Simak; Siwicka, Aleksandra; Brackow, Jan; Scheiper, Bodo
PATENT ASSIGNEE(S): Emory University, USA; Imperial College of Science and Technology
SOURCE: PCT Int. Appl., 201pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008151304	A1	20081211	WO 2008-US65988	20080605
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRIORITY APPLN. INFO.: US 2007-942198P P 20070605

OTHER SOURCE(S): MARPAT 150:35382

GI



I



II

AB This invention provides a class of compds. of formula I which are useful for specifically inhibiting cyclin-dependent kinases. This class of compds. of formula I finds use in treating diseases resulting from inappropriate activity of cyclin-dependent kinases. Moreover, certain members of this class are particularly useful for inhibiting cyclin-dependent kinase 7 and are especially useful for the treatment of breast cancer. Compds. of formula I wherein R is C1-6 hydrocarbyl; R1 is OH, alkoxy, H and halo; R2 is H, alkyl, amino, sulfanyl, and sulfonyl; R3 is H, SO₂NH₂ and derivs., halo, alkoxy, etc.; R4 is H, halo, alkoxy, OH, (un)substituted C1-6 hydrocarbyl; R5 is H, OH, alkoxy, halo, and linear, branched or cyclic chain with between 1 - 8 carbon atoms; X is H, C1-4 hydrocarbyl, halo, (un)substituted hydroxyalkyl, (un)substituted aminoalkyl, (un)substituted alkoxyalkyl, etc.; are claimed. Example compound II was prepared by amination of 3-isopropyl-5,7-dichloropyrazolo[1,5-a]pyrimidine; the resulting N-benzyl-5-chloro-3-isopropylpyrazolo[1,5-a]pyrimidin-7-amine underwent Boc-protection with Boc-anhydride to give the corresponding Boc-protected amine, which underwent amination with isopropylamine to give tert-Bu benzyl-3-isopropyl-5-(isopropylamino)pyrazolo[1,5-a]pyrimidin-7-ylcarbamate, which underwent hydrolysis to give compound II. All the invention compds. were evaluated for their cyclin-dependent kinase inhibitory activity (data given).


IT 771499-34-4P 771499-44-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazolopyrimidinamine compds. as cyclin-dependent kinase selective inhibitors useful in treatment and prevention of cyclin-dependent kinase-mediated diseases)

RN 771499-34-4 CAPLUS


CN Benzenesulfonamide, 4-[[5-chloro-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771499-44-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 2
 ACCESSION NUMBER: 2006:152759 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 144:233090
 TITLE: Preparation of pyrazolo[1,5-a]pyrimidine derivatives as MAPKAP-K2 inhibitors
 INVENTOR(S): Kosugi, Tomomi; Imai, Minoru; Makino, Hiroaki; Takakuwa, Mika; Unoki, Gen; Kataoka, Kenichiro; Mitchell, Dale Robert; Simpson, Donald James; Harris, Clifford John; Le, Joelle; Yamakoshi, Yuko
 PATENT ASSIGNEE(S): Teijin Pharma Limited, Japan
 SOURCE: PCT Int. Appl., 124 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006016715	A1	20060216	WO 2005-JP15031	20050811
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005272298	A1	20060216	AU 2005-272298	20050811
CA 2576949	A1	20060216	CA 2005-2576949	20050811
EP 1780212	A1	20070502	EP 2005-780390	20050811
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101039945	A	20070919	CN 2005-80035081	20050811
BR 2005014187	A	20080603	BR 2005-14187	20050811
US 20060135514	A1	20060622	US 2005-202035	20050812
IN 2007DN00618	A	20070817	IN 2007-DN618	20070123
MX 200701208	A	20071003	MX 2007-1208	20070130
KR 2007051325	A	20070517	KR 2007-705730	20070312


PRIORITY APPLN. INFO.:

JP 2004-236035
US 2004-603535P
WO 2005-JP15031A 20040813
P 20040824
W 20050811

OTHER SOURCE(S):

MARPAT 144:233090

GI



AB The title compds. I [R1 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; R2 = H, halo, CN, etc.; R3 = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, etc.; R4 = H, halo, (un)substituted alkyl, etc.; R5 = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, etc.; Y = O, S; a proviso is given] are prepared I are useful in the treatment of MAPKAP-K2 mediated diseases, for example, inflammatory diseases, autoimmune diseases, osteoclastic disorder, etc. Thus, (dl)-(4-ethoxyphenyl)-[6-methyl-5-(trans-4-propylpiperidin-3-yloxy)pyrazolo[1,5-a]pyrimidin-7-yl]amine was prepared by catalytic hydrogenation of (dl)-trans-4-Allyl-3-[7-(4-ethoxyphenylamino)-6-methylpyrazolo[1,5-a]pyrimidin-5-yloxy]piperidine-1-carboxylic acid benzyl ester. Many compds. of this invention showed IC50 values $\leq 2 \mu\text{M}$ against MAPKAP-K2 (mitogen activated protein kinase-activated protein kinase-2).


IT 876389-55-8P 876389-56-9P 876389-57-0P
876389-70-7P 876390-39-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[1,5-a]pyrimidine derivs. as MAPKAP-K2 inhibitors)


RN 876389-55-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(3-chloro-4-fluorophenyl)-5-methoxy- (CA INDEX NAME)




RN 876389-56-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(3-chloro-4-fluorophenyl)-5-[(4-methoxyphenyl)methoxy]- (CA INDEX NAME)



RN 876389-57-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-5(4H)-one, 7-[(3-chloro-4-fluorophenyl)amino]-
(CA INDEX NAME)



RN 876389-70-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-[(cis-4-aminocyclohexyl)oxy]-N-(3-chloro-4-fluorophenyl)-3-iodo- (CA INDEX NAME)

Relative stereochemistry.




RN 876390-39-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(3-chloro-4-fluorophenyl)-5-(methylthio)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 876390-38-4
 CMF C13 H10 Cl F N4 S




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




IT 754211-11-5P 754211-17-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrazolo[1,5-a]pyrimidine derivs. as MAPKAP-K2 inhibitors)
 RN 754211-11-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3,5-dichloro-N-(3-chloro-4-fluorophenyl)-
 (CA INDEX NAME)



RN 754211-17-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(3-chloro-4-fluorophenyl)-3-


(methylthio)- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 3
 ACCESSION NUMBER: 2005:347001 CAPLUS Full-text
 DOCUMENT NUMBER: 142:392433
 TITLE: Preparation of fused heterocyclic compounds as c-Jun N-terminal kinase inhibitors
 INVENTOR(S): Yoshizawa, Toshio; Ogawa, Koji; Fujita, Setsuko; Inohara, Takeo; Ohmoto, Kazuyuki
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 98 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035516	A1	20050421	WO 2004-JP14941	20041008
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1671962	A1	20060621	EP 2004-792210	20041008
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
US 20070060595	A1	20070315	US 2006-575350	20060602
PRIORITY APPLN. INFO.:			JP 2003-352585	A 20031010
			JP 2004-13672	A 20040121
			WO 2004-JP14941	W 20041008
OTHER SOURCE(S):	MARPAT 142:392433			
GI				



AB Title compds. represented by the formula I [wherein ring AB = fused heterocycle; R1 = H, halo, cyano, oxo, (protected)hydroxy, (protected)carboxy, etc.; and pharmaceutically acceptable salts, solvates or their prodrugs thereof] were prepared as c-Jun N-terminal kinase (JNK) inhibitors. For example, reaction of 5,7-dichloropyrazolo[1,5-a]pyrimidine with 3-chloroaniline gave II. II showed inhibition of human JNK1 with an IC50 value of 0.33 $\mu\text{mol/l}$. Thus, I and their pharmaceutical compns. are useful as JNK inhibitors for the treatment of metabolic diseases, such as diabetes, and inflammatory disease, e.g., articular rheumatism (no data).


IT 850140-36-2P 850140-38-4P 850140-52-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[1,5-a]pyrimidine and chromen amines as JNK1 kinase inhibitors)


RN 850140-36-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(3-chlorophenyl)- (CA INDEX NAME)




RN 850140-38-4 CAPLUS

CN Benzeneethanol, 4-[(5-chloropyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)



RN 850140-52-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-(3-furanyl)-N-(3,4,5-trimethoxyphenyl)-
(CA INDEX NAME)REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2004:857603 CAPLUS Full-text

DOCUMENT NUMBER: 141:332189

TITLE: Pyrazolopyrimidine compounds and their use in medicine

INVENTOR(S): Parratt, Martin; Bower, Justin Fairfield; Williamson,
Douglas; Cansfield, Andrew

PATENT ASSIGNEE(S): Vernalis Cambridge Limited, UK

SOURCE: PCT Int. Appl., 90 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087707	A1	20041014	WO 2004-GB1214	20040318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				


ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
 TD, TG

EP 1608652	A1	20051228	EP 2004-721593	20040318
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
US 20070179161	A1	20070802	US 2006-551177	20061206
PRIORITY APPLN. INFO.:			GB 2003-7389	A 20030331
			GB 2003-12296	A 20030529
			GB 2003-19028	A 20030813
			GB 2003-25854	A 20031105
			WO 2004-GB1214	W 20040318

OTHER SOURCE(S): MARPAT 141:332189
 GI



I



II

AB Compds. of formula (I) or salts, N-oxides, hydrates or solvates thereof are disclosed as inhibitors of kinase activity, and useful for the treatment of, for example, cancer, psoriasis or restenosis: wherein ring A is an optionally substituted carbocyclic or heterocyclic radical. Alk represents an optionally substituted divalent C1-C6 alkylene radical; n is 0 or 1. Q represents a radical of formula -(Alk1)p (X)r-(Alk2)s -Z wherein in any compatible combination Z is hydrogen or an optionally substituted carbocyclic or heterocyclic ring; Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene radicals which may contain a -O-, -S- or -NRA- link, wherein RA is hydrogen or C1-C6 alkyl; X represents -O-, -S-, -(C=O)-, -(C=S)-, -SO2-, -SO-, -C(=O)O-, -OC(=O)-, -C(=O)NRA-, -NRAC(=O)-, -C(=S)NRA-, -NRAC(=S)-, -SO2NRA-, -NRASO2-, -OC(=O)NRA-, -NRAC(=O)O-, or -NRA- wherein RA is hydrogen or C1-C6 alkyl; p, r and s are independently 0 or 1. R1 represents a radical -(Alk3)a-(Y)b-(Alk4)d-B wherein a, b and d are independently 0 or 1; Alk3 and Alk4 are optionally substituted divalent C1-C3 alkylene radicals; Y represents a monocyclic divalent carbocyclic or heterocyclic radical having from 5 to 8 ring atoms, -O-, -S-, or -NRA- wherein RA is hydrogen or C1-C6 alkyl; B represents hydrogen or halo, or an optionally substituted monocyclic carbocyclic or heterocyclic ring having from 5 to 8 ring atoms, or in the case where Y is -NRA- and b is 1, then RA and the radical -(Alk4)d-B taken together with the nitrogen to which they are attached may form an optionally substituted heterocyclic ring. R represents H, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, Ph, benzyl, cycloalkyl with 3 to 6 ring atoms, or a


monocyclic heterocyclic group having 5 or 6 ring atoms. Preparation of I is also disclosed; thus, e.g., the HCl salt of II was prepared from 5,7-dichloropyrazolo[1,5-a]pyrimidine via substitution with 4-fluoroaniline followed by N-protection with di-t-Bu dicarbonate, coupling with Ph boronic acid, and deprotection. I were assayed for CDK2 inhibition and were identified to possess IC50 values ranging from 0.004-24.866 μ M. Data for assays of CHK1 kinase activity and PDK dependent kinase activity were given as well as growth inhibition assay data for select example compds.

IT 771499-17-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of aminopyrazolopyrimidines with kinase inhibitory activity)

RN 771499-17-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-3-(1-methylethyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



IT 676366-29-3P 771497-77-9P 771497-84-8P
771498-34-1P 771498-41-0P 771498-48-7P
771498-55-6P 771498-61-4P 771498-67-0P
771498-73-3P 771498-78-3P 771498-83-0P
771498-88-5P 771498-97-6P 771499-02-6P
771499-07-1P 771499-12-8P 771499-22-0P
771499-34-4P 771499-39-9P 771499-44-6P
771499-50-4P 771499-55-9P 771499-60-6P
771499-65-1P 771499-70-8P 771499-75-3P
771499-80-0P 771499-85-5P 771499-90-2P
771499-95-7P 771500-00-6P 771500-05-1P
771500-11-9P 771500-16-4P 771500-21-1P
771500-26-6P 771500-30-2P 771500-36-8P
771500-41-5P 771500-46-0P 771500-51-7P
771500-57-3P 771500-64-2P 771500-70-0P
771500-75-5P 771500-83-5P 771500-89-1P
771500-95-9P 771501-01-0P 771501-07-6P
771501-12-3P 771501-17-8P 771501-23-6P
771501-28-1P 771501-34-9P 771501-40-7P
771501-46-3P 771501-53-2P 771501-59-8P
771501-66-7P 771501-72-5P 771501-78-1P
771501-84-9P 771501-90-7P 771501-96-3P
771502-21-7P 771502-27-3P 771502-33-1P
771502-39-7P 771502-45-5P 771502-51-3P
771502-57-9P 771502-63-7P 771502-75-1P


771502-81-9P 771502-87-5P 771502-93-3P
 771502-99-9P 771503-05-0P 771503-12-9P
 771503-18-5P 771503-24-3P 771503-30-1P
 771503-36-7P 771503-42-5P 771503-48-1P
 771503-54-9P 771503-61-9P 771503-67-4P
 771503-73-2P 771503-79-9P 771503-85-6P
 771503-91-4P 771503-97-0P 771504-03-1P
 771504-15-5P 771504-21-3P 771504-27-9P
 771504-34-8P 771504-40-6P 771504-46-2P
 771504-52-0P 771504-58-6P 771504-64-4P
 771504-70-2P 771504-77-9P 771504-86-0P
 771504-93-9P 771505-00-1P 771505-08-9P
 771505-14-7P 771505-20-5P 771505-26-1P
 771505-32-9P 771505-38-5P 771505-44-3P
 771505-50-1P 771505-56-7P 771505-61-4P
 771505-67-0P 771505-73-8P 771505-79-4P
 771505-85-2P 771505-91-0P 771505-96-5P
 771506-02-6P 771506-08-2P 771506-19-5P
 771506-25-3P 771506-31-1P 771506-42-4P
 771506-48-0P 771506-54-8P 771506-60-6P
 771506-66-2P 771506-72-0P 771506-78-6P
 771506-84-4P 771506-96-8P 771507-02-9P
 771507-07-4P 771507-13-2P 771507-19-6P
 771507-31-4P 771507-42-7P 771507-48-3P
 771507-54-1P 771507-60-9P 771507-66-5P
 771507-72-3P 771507-78-9P 771507-84-7P
 771507-90-5P 771508-02-2P 771508-08-8P
 771508-14-6P 771508-20-4P 771508-26-0P
 771508-32-8P 771508-38-4P 771508-44-2P
 771508-51-1P 771508-58-8P 771508-72-6P
 771508-79-3P 771509-86-2P 771508-92-0P
 771509-98-6P 771509-26-3P 771509-32-1P
 771509-38-7P 771509-43-4P 771509-49-0P
 771509-55-8P 771509-61-6P 771509-67-2P
 771509-73-0P 771509-79-6P 771509-85-4P
 771509-97-8P 771533-40-5P 771533-41-6P
 771533-42-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of aminopyrazolopyrimidines with kinase
 inhibitory activity)


RN 676366-29-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-chloro-N-[4-
 (methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 771497-77-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(4-fluorophenyl)-5-phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 771497-84-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-(3,5-dimethyl-4-isoxazolyl)-N-(4-fluorophenyl)- (CA INDEX NAME)




RN 771498-34-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[4-(4-morpholinylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771498-41-0 CAPLUS

CN Benzenesulfonamide, 4-[(5-chloropyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-2-pyridinyl- (CA INDEX NAME)




RN 771498-48-7 CAPLUS

CN Benzenesulfonamide, 4-[(5-chloropyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-2-thiazolyl- (CA INDEX NAME)




RN 771498-55-6 CAPLUS

CN Benzenesulfonamide, 4-[(5-chloropyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 771498-61-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-(3-methylphenyl)-N-[4-(4-morpholinylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771498-67-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-(cyclohexyloxy)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-2-thiazolyl- (CA INDEX NAME)




RN 771498-73-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771498-78-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[4-(4-morpholinylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771498-83-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-(3-methylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-2-thiazolyl- (CA INDEX NAME)




RN 771498-88-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[4-(methanesulfonyl)phenyl]- (CA INDEX NAME)




RN 771498-97-6 CAPLUS

CN Benzenesulfonamide, 4-(pyrazolo[1,5-a]pyrimidin-7-ylamino)- (CA INDEX NAME)




RN 771499-02-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-(cyclohexyloxy)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771499-07-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-(cyclohexyloxy)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 771499-12-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[4-(methylsulfonyl)phenyl]-3-(phenylmethyl)- (CA INDEX NAME)




RN 771499-22-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-(cyclohexyloxy)-3-(1-methylethyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771499-34-4 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771499-39-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-3-(1-methylethyl)-N-[4-(1-pyrrolidinylsulfonyl)phenyl]- (CA INDEX NAME)



RN 771499-44-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771499-50-4 CAPLUS


CN Benzenesulfonamide, 4-[5-[(trans-4-aminocyclohexyl)amino]-3-bromopyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.




RN 771499-55-9 CAPLUS

CN Benzenesulfonamide, 4-[5-chloro-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 771499-60-6 CAPLUS

CN 4-Piperidinol, 1-[[4-[[5-chloro-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]phenyl]sulfonyl]- (CA INDEX NAME)




RN 771499-65-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-(2-hydroxyethyl)-N-methyl- (CA INDEX NAME)




RN 771499-70-8 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 771499-75-3 CAPLUS

CN Benzenesulfonamide, 4-[(5-chloro-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 771499-80-0 CAPLUS

CN Benzenesulfonamide, 4-[(5-chloro-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 771499-85-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methylethyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771499-90-2 CAPLUS

CN Benzenesulfonamide, 4-[[5-[2-(dimethylamino)ethoxy]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-(2-hydroxyethyl)-N-methyl- (CA INDEX NAME)




RN 771499-95-7 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-[[3-(1-methylethyl)-5-(2-methylpropoxy)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 771500-00-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methylethyl)-5-(2-methylpropoxy)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771500-05-1 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-N-methyl-4-[[3-(1-methylethyl)-5-(2-methylpropoxy)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 771500-11-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-3-ethyl-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771500-16-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-ethyl-5-(2-methylpropoxy)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771500-21-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, 3-ethyl-N5,N5-dimethyl-N7-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771500-26-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-chloro-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-methyl- (CA INDEX NAME)




RN 771500-30-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-ethyl-N-[4-(methanesulfonyl)phenyl]- (CA INDEX NAME)




RN 771500-36-8 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-4-[[5-(4-hydroxy-1-piperidinyl)-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-methyl- (CA INDEX NAME)




RN 771500-41-5 CAPLUS

CN Benzenesulfonamide, 4-[[5-[3-(hydroxymethyl)-1-piperidiny]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771500-46-0 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-[[3-(1-methylethyl)-5-(1-piperidinyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 771500-51-7 CAPLUS

CN Benzenesulfonamide, 4-[[5-(diethylamino)-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-(2-hydroxyethyl)-N-methyl- (CA INDEX NAME)




RN 771500-57-3 CAPLUS

CN Benzenesulfonamide, 4-[(5-chloro-3-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771500-64-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-[2-(dimethylamino)ethoxy]-3-(1-methylethyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771500-70-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-(cyclopentylloxy)-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771500-75-5 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-4-[[5-[3-(hydroxymethyl)-1-piperidinyl]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-methyl- (CA INDEX NAME)



RN 771500-83-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-ethyl-3-(1-methylethyl)-N7-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 771500-89-1 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-ethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.




RN 771500-95-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-[2-(dimethylamino)ethyl]-N5-methyl-3-(1-methylethyl)-N7-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771501-01-0 CAPLUS

CN Ethanol, 2-[methyl[3-(1-methylethyl)-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]- (CA INDEX NAME)



RN 771501-07-6 CAPLUS


CN Benzenesulfonamide, 4-[[5-chloro-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-(2-(dimethylamino)ethyl)-N-methyl- (CA INDEX NAME)



RN 771501-12-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-methyl- (CA INDEX NAME)

Relative stereochemistry.




RN 771501-17-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,


N5-(trans-4-aminocyclohexyl)-3-(1-methylethyl)-N7-[4-(1-pyrrolidinylsulfonyl)phenyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 771501-23-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-(cyclohexylamino)-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771501-28-1 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-[[5-(1-methylethoxy)-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 771501-34-9 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-[[3-(1-methylethyl)-5-[(1-methyl-2-pyrrolidinyl)methoxy]pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 771501-40-7 CAPLUS


CN Benzenesulfonamide, 4-[[5-methoxy-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771501-46-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 771501-53-2 CAPLUS


CN Benzenesulfonamide, 4-[[5-chloro-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-[2-(dimethylamino)ethyl]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 771501-59-8 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-[[3-(1-methylethyl)-5-[(1-methyl-4-piperidinyl)amino]pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 771501-66-7 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-[[3-(1-methylethyl)-5-[(1-methyl-3-pyrrolidinyl)oxy]pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 771501-72-5 CAPLUS


CN Benzenesulfonamide, 4-[[5-(diethylamino)-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771501-78-1 CAPLUS


CN Benzenesulfonamide, N-[[2-(dimethylamino)ethyl]-N-methyl-4-[[3-(1-

methylethyl)-5-(2-methylpropoxy)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA
INDEX NAME)




RN 771501-84-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-[7-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-5-yl]- (CA INDEX NAME)




RN 771501-90-7 CAPLUS

CN Benzenesulfonamide, 4-[[5-[[3-(dimethylamino)propyl]methylamino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771501-96-3 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-[[3-(1-methylethyl)-5-[(1-methyl-3-piperidinyl)oxy]pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 771502-21-7 CAPLUS


CN Benzenesulfonamide, 4-[(3-bromo-5-chloropyrazolo[1,5-a]pyrimidin-7-yl)amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771502-27-3 CAPLUS


CN Benzenesulfonamide, 4-[[5-chloro-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-

7-yl]amino]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 771502-33-1 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[7-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-5-yl]- (CA INDEX NAME)




RN 771502-39-7 CAPLUS

CN Acetamide, N-[trans-4-[[7-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-5-yl]amino]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 771502-45-5 CAPLUS
 CN Benzenesulfonamide, N,N-dimethyl-4-[[3-(1-methylethyl)-5-[(4-piperidinylmethyl)amino]pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 771502-51-3 CAPLUS
 CN Benzenesulfonamide, 4-[[5-[2-(dimethylamino)ethoxy]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-(2-hydroxyethyl)-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 771502-57-9 CAPLUS
 CN 3-Piperidinecarboxylic acid, 1-[7-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-5-yl]- (CA INDEX NAME)



RN 771502-63-7 CAPLUS


CN Benzenesulfonamide, 4-[[5-[[[(1R)-1-(hydroxymethyl)propyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 771502-75-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-(cyclopentylamino)-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-(2-hydroxyethyl)-N-methyl- (CA INDEX NAME)




RN 771502-81-9 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[trans-4-[[7-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethyl)pyrazolo[1,5-


a[pyrimidin-5-yl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 771502-87-5 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-[[3-(1-methylethyl)-5-[methyl(1-methyl-4-piperidinyl)amino]pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 771502-93-3 CAPLUS

CN Acetamide, 2-[[7-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-5-yl]oxy]-N,N-diethyl- (CA INDEX NAME)




RN 771502-99-9 CAPLUS

CN Benzenesulfonamide, 4-[[5-[3-[(dimethylamino)methyl]-1-piperidinyl]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771503-05-0 CAPLUS

CN Benzenesulfonamide, N-[2-(dimethylamino)ethyl]-4-[[3-(1-methylethyl)-5-(2-methylpropoxy)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 771503-12-9 CAPLUS

CN Benzenesulfonamide, 4-[[5-(cyclohexyloxy)-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 771503-18-5 CAPLUS

CN 3-Piperidinecarboxamide, 1-[7-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-5-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 771503-24-3 CAPLUS


CN Benzenesulfonamide, 3-[(3-bromo-5-chloropyrazolo[1,5-a]pyrimidin-7-yl)amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771503-30-1 CAPLUS

CN Benzenesulfonamide, 3-[[5-[(trans-4-aminocyclohexyl)amino]-3-bromopyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771503-36-7 CAPLUS
 CN Benzenesulfonamide, 4-[[5-[4-(aminomethyl)-1-piperidinyl]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771503-42-5 CAPLUS
 CN Benzenesulfonamide, 4-[[5-chloro-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)




RN 771503-48-1 CAPLUS
 CN Benzenesulfonamide, 4-[[5-[(2S)-2-(aminomethyl)-1-pyrrolidinyl]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 771503-54-9 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(2-aminoethyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771503-61-8 CAPLUS


CN Formic acid, compd. with 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-[2-(dimethylamino)ethyl]-N-methylbenzenesulfonamide (2:1) (CA INDEX NAME)

CM 1

CRN 771503-60-7

CMF C26 H40 N8 O2 S

Relative stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2



RN 771503-67-4 CAPLUS

CN Benzenesulfonamide, 4-[[5-[[trans-4-(diethylamino)cyclohexyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771503-73-2 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(trans-4-hydroxycyclohexyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.




RN 771503-79-8 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-[[3-(1-methylethyl)-5-[[3-(4-morpholinyl)propyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 771503-85-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(3-aminocyclohexyl)amino]-3-bromopyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771503-91-4 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(2-(hydroxymethyl)-1-pyrrolidinyl)-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771503-97-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-[4-[(dimethylamino)methyl]-1-piperidiny]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771504-03-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771504-15-5 CAPLUS

CN Benzenesulfonamide, 4-[[5-(ethylamino)-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771504-21-3 CAPLUS


CN Benzenesulfonamide, N,N-dimethyl-4-[[3-(1-methylethyl)-5-[4-[(1-methyl-4-piperidinyl)methyl]-1-piperazinyl]pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 771504-27-9 CAPLUS

CN Benzenesulfonamide, 4-[[5-[[[trans-4-[(ethylamino)carbonyl]amino]cyclohexyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.




RN 771504-34-8 CAPLUS

CN Formic acid, compd. with N,N-dimethyl-4-[[3-(1-methylethyl)-5-(4-pyridinylamino)pyrazolo[1,5-a]pyrimidin-7-yl]amino]benzenesulfonamide (1:1) (CA INDEX NAME)

CM 1

CRN 771504-33-7

CMF C22 H25 N7 O2 S



CM 2


CRN 64-18-6

CMF C H2 O2




RN 771504-40-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethyl)-, ethyl ester (CA INDEX NAME)



RN 771504-46-2 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(3-aminocyclohexyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771504-52-0 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)oxy]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.



RN 771504-58-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 7-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-N-ethyl-3-(1-methylethyl)- (CA INDEX NAME)



RN 771504-64-4 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(cis-4-aminocyclohexyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.




RN 771504-70-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxylic acid, 7-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethyl)- (CA INDEX NAME)



RN 771504-77-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide,
N-(2-aminoethyl)-7-[4-[(dimethylamino)sulfonyl]phenyl]amino]-3-(1-
methylethyl)- (CA INDEX NAME)




RN 771504-86-0 CAPLUS

CN Formic acid, compd. with N,N-dimethyl-4-[[3-(1-methylethyl)-5-(methyl-4-pyridinylamino)pyrazolo[1,5-a]pyrimidin-7-yl]amino]benzenesulfonamide (1:1) (CA INDEX NAME)

CM 1

CRN 771504-85-9

CMF C23 H27 N7 O2 S



CM 2


CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 771504-93-9 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(4-hydroxy-1-piperidiny)carbonyl]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771505-00-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 7-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 771505-08-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, N-[2-(dimethylamino)ethyl]-7-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethyl)- (CA INDEX NAME)




RN 771505-14-7 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(4-amino-1-piperidinyl)carbonyl]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771505-20-5 CAPLUS


CN Benzenesulfonamide, N,N-dimethyl-4-[[3-(1-methylethyl)-5-[[3-(4-methyl-1-piperazinyl)propyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 771505-26-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-[[trans-4-(dipropylamino)cyclohexyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771505-32-9 CAPLUS


CN Benzenesulfonamide, N,N-dimethyl-4-[[3-(1-methylethyl)-5-[[trans-4-[(methylsulfonyl)amino]cyclohexyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.



RN 771505-38-5 CAPLUS


CN Benzenesulfonamide, 4-[(5-chloro-3-cyclopropylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771505-44-3 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-cyclopropylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.




RN 771505-50-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-(3-amino-1-pyrrolidinyl)-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771505-56-7 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-[[3-(1-methylethyl)-5-[[4-(1-pyrrolidinyl)-1-piperidinyl]carbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 771505-61-4 CAPLUS


CN Benzenesulfonamide, 4-[[5-[[4-(aminomethyl)-1-piperidinyl]carbonyl]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771505-67-0 CAPLUS


CN Benzenesulfonamide, 4-[[5-[[[(1R,2S)-2-aminocyclohexyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 771505-73-8 CAPLUS


CN 4-Piperidinecarboxamide, 1-[[7-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-5-yl]carbonyl]-N-methyl- (CA INDEX NAME)



RN 771505-79-4 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.




RN 771505-85-2 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-chloropyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 771505-91-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-chloro-N-[4-(phenylsulfonyl)phenyl]- (CA INDEX NAME)



RN 771505-96-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(trans-4-aminocyclohexyl)-3-bromo-N7-[4-(phenylsulfonyl)phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 771506-02-6 CAPLUS


CN Benzenesulfonamide, 4-[[5-[[[(1R,2S)-2-aminocyclohexyl]amino]-3-bromopyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 771506-08-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-chloro-N-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 771506-19-5 CAPLUS


CN Benzenesulfonamide, 4-[[5-[[[trans-4-[(aminocarbonyl)amino]cyclohexyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 771506-25-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-3-ethyl-N-[4-(1-pyrrolidinylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771506-31-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-chloro-N-[4-(1-pyrrolidinylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771506-42-4 CAPLUS

CN Benzamide, 4-[(3-bromo-5-chloropyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)



RN 771506-48-0 CAPLUS


CN Benzenesulfonamide, 4-[[5-(hydroxymethyl)-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771506-54-8 CAPLUS

CN Benzenesulfonamide, 4-[[5-[[trans-4-(ethylamino)cyclohexyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771506-60-6 CAPLUS


CN Benzenesulfonamide, 4-[[5-[[trans-4-(aminocyclohexyl)amino]-3-chloropyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.




RN 771506-66-2 CAPLUS

CN Benamide, 4-[(5-chloro-3-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 771506-72-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(3-aminocyclopentyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771506-78-6 CAPLUS

CN Benzenesulfonamide, 4-[(5-chloro-3-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-2-thiazolyl- (CA INDEX NAME)



RN 771506-84-4 CAPLUS


CN Benamide, 4-[(5-chloro-3-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[2-(diethylamino)ethyl]- (CA INDEX NAME)



RN 771506-96-8 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-(3-thienyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.




RN 771507-02-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide,
7-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-N-[2-(methylamino)ethyl]-3-(1-methylethyl)- (CA INDEX NAME)



RN 771507-07-4 CAPLUS


CN Benzenesulfonamide, 4-[[5-chloro-3-(3-thienyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771507-13-2 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(4-amino-1-piperidinyl)methyl]-3-(1-


methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771507-19-8 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)oxy]-3-bromopyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.



RN 771507-31-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-chloro-N-(3-chlorophenyl)- (CA INDEX NAME)



RN 771507-42-7 CAPLUS

CN Benzenesulfonamide, 4-[15-[[trans-4-(dimethylamino)cyclohexyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771507-48-3 CAPLUS

CN Benzenesulfonamide, 4-[15-[(trans-4-aminocyclohexyl)amino]-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771507-54-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(cis-4-aminocyclohexyl)-3-bromo-N7-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 771507-60-9 CAPLUS


CN Benamide, 4-[[5-[(cis-4-aminocyclohexyl)amino]-3-bromopyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.



RN 771507-66-5 CAPLUS


CN Benzenesulfonamide, 4-[[3-bromo-5-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-2-thiazolyl- (CA INDEX NAME)



RN 771507-72-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-cyclopentylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771507-78-9 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)oxy]-3-chloropyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771507-84-7 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.



RN 771507-90-5 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(4-hydroxy-1-piperidinyl)methyl]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771508-02-2 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl-2-(methylthio)- (CA INDEX NAME)


Relative stereochemistry.



RN 771508-08-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(cis-4-aminocyclohexyl)-3-ethyl-N7-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 771508-14-6 CAPLUS

CN Benzamide, 4-[[5-[(cis-4-aminocyclohexyl)amino]-3-ethylpyrazolo[1,5-


a[pyrimidin-7-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.



RN 771508-20-4 CAPLUS


CN Benzenesulfonamide, 4-[[3-ethyl-5-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771508-26-0 CAPLUS

CN Cyclohexanol, 4-[[3-bromo-7-[[4-(1-pyrrolidinylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 771508-32-8 CAPLUS

CN Benzenesulfonamide, 4-[5-[(cis-4-aminocyclohexyl)amino]-3-bromopyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-2-thiazolyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771508-38-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(cis-4-aminocyclohexyl)-3-bromo-N7-[4-(1-pyrrolidinylsulfonyl)phenyl]-
(CA INDEX NAME)

Relative stereochemistry.



RN 771508-44-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
3-(1-methylethyl)-N7-[4-(1-pyrrolidinylsulfonyl)phenyl]-N5-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 771508-51-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-bromopyrazolo[1,5-a]pyrimidin-7-yl]amino]-2-chloro-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771508-58-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(trans-4-aminocyclohexyl)-3-bromo-N7-(4-phenoxyphenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 771508-72-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
 N5-(trans-4-aminocyclohexyl)-3-chloro-N7-[4-(phenylsulfonyl)phenyl]- (CA
 INDEX NAME)


Relative stereochemistry.



RN 771508-79-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-[(trans-4-aminocyclohexyl)oxy]-3-bromo-
 N-[4-(phenylsulfonyl)phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 771508-86-2 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-
 bromopyrazolo[1,5-a]pyrimidin-7-yl]amino]-2-methoxy-N,N-dimethyl- (CA
 INDEX NAME)


Relative stereochemistry.



RN 771508-92-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-[(trans-4-aminocyclohexyl)oxy]-3-chloro-N-[4-(phenylsulfonyl)phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 771508-98-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(trans-4-aminocyclohexyl)-3-chloro-N7-(4-phenoxyphenyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 771509-26-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3,5-dichloro-N-[4-(2-thienylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771509-32-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
 N5-(trans-4-aminocyclohexyl)-3-chloro-N7-[4-(3-pyridinyloxy)phenyl]- (CA
 INDEX NAME)

Relative stereochemistry.




RN 771509-38-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
 N5-(trans-4-aminocyclohexyl)-3-chloro-N7-[4-(4-fluorophenoxy)phenyl]- (CA
 INDEX NAME)

Relative stereochemistry.




RN 771509-43-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
 N5-(trans-4-aminocyclohexyl)-3-chloro-N7-[4-[(5-chloro-3-
 pyridinyl)oxy]phenyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 771509-49-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
 N5-(trans-4-aminocyclohexyl)-3-chloro-N7-(3-chlorophenyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 771509-55-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
 N5-(trans-4-aminocyclohexyl)-3-chloro-N7-[4-(2-thienylthio)phenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 771509-61-6 CAPLUS
 CN Benzenesulfonamide, N,N-dimethyl-4-[[3-(1-methylethyl)-5-[(3S)-3-pyrrolidinylamino]pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 771509-67-2 CAPLUS

CN Benzenesulfonamide, 4-[[3-chloro-5-[(3R)-3-pyrrolidinyloxy]pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 771509-73-0 CAPLUS

CN Benzenesulfonamide, 4-[[3-chloro-5-[(3S)-3-pyrrolidinyloxy]pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 771509-79-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-(methylthio)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771509-85-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-[4-[(5-chloro-3-pyridinyl)oxy]phenyl]-3-
(methylthio)- (CA INDEX NAME)


Relative stereochemistry.



RN 771509-97-8 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(cis-4-aminocyclohexyl)amino]-3-
(methylsulfonyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl-1-
chloro-3-pyridin-2-yl (CA INDEX NAME)

Relative stereochemistry.



RN 771533-40-5 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(3-methylphenyl)pyrazolo[1,5-a]pyrimidin-7-
yl]amino]-N-2-pyridinyl- (CA INDEX NAME)



RN 771533-41-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(cis-4-aminocyclohexyl)amino]-3-bromopyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771533-42-7 CAPLUS

CN Cyclohexanol, 4-[[3-bromo-7-[[4-(phenylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



IT 771497-98-4 771498-05-6 771498-12-5


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(drug candidate; preparation of aminopyrazolopyrimidines with kinase inhibitory activity)


RN 771497-98-4 CAPLUS

CN Phenol, 4-[7-(phenylamino)pyrazolo[1,5-a]pyrimidin-5-yl]- (CA INDEX NAME)




RN 771498-05-6 CAPLUS

CN Phenol, 4-[7-[(3-chlorophenyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]- (CA INDEX NAME)



RN 771498-12-5 CAPLUS

CN Phenol, 3-[7-(phenylamino)pyrazolo[1,5-a]pyrimidin-5-yl]- (CA INDEX NAME)




IT 771510-50-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of aminopyrazolopyrimidines with kinase inhibitory activity)

RN 771510-50-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(4-fluorophenyl)- (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 5
 ACCESSION NUMBER: 2004:740331 CAPLUS Full-text
 DOCUMENT NUMBER: 141:260763
 TITLE: Preparation of pyrazolo[1,5-a]pyrimidines for treating or preventing protein kinase mediated disorders
 INVENTOR(S): Kataoka, Kenichiro; Suzuki, Naotaka; Kosugi, Tomomi; Imai, Minoru; Makino, Hiroaki; Takakuwa, Mika; Unoki, Gen; Fujino, Aiko; Oue, Yasuhiro; Yamakoshi, Yuko; Sugiura, Satoshi; Mitchell, Dale Robert; Simpson, Donald James; Harris, Clifford John; Le, Joelle
 PATENT ASSIGNEE(S): Teijin Pharma Limited, Japan
 SOURCE: PCT Int. Appl., 380 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076458	A1	20040910	WO 2004-JP2522	20040301
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
AU 2004215481	A1	20040910	AU 2004-215481	20040301
CA 2516824	A1	20040910	CA 2004-2516824	20040301
EP 1599482	A1	20051130	EP 2004-716064	20040301
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
BR 2004007834	A	20060214	BR 2004-7834	20040301
CN 1780840	A	20060531	CN 2004-80011183	20040301
JP 2006519226	T	20060824	JP 2006-502687	20040301
IN 2005DN03714	A	20070420	IN 2005-DN3714	20050822
MX 2005008955	A	20060222	MX 2005-8955	20050823
ZA 2005006744	A	20060628	ZA 2005-6744	20050823
NO 2005003955	A	20050922	NO 2005-3955	20050825
US 20060189632	A1	20060824	US 2006-547080	20060505
PRIORITY APPLN. INFO.:			GB 2003-4665	A 20030228


US 2003-500695P
GB 2003-29446
WO 2004-JP2522

P 20030908
A 20031219
A 20040301

OTHER SOURCE(S):

MARPAT 141:260763

GI



AB The tile compds. [I; R1 = H, alkyl, alkenyl, cycloalkyl, etc.; R2 = H, halo, CN, NO2, CHO, etc.; R3 = alkyl, cycloalkyl, aryl, etc.; R4 = H, halo, alkyl, cycloalkyl, etc.; R5 = alkyl, alkenyl, cycloalkyl, heterocyclyl, etc.; R6 = H, alkyl, cycloalkyl, aryl, etc.; with the provisos] which exhibit excellent kinase inhibiting activity (particularly MAPKAP-K2 inhibiting activity) and therefore are expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumor growth, were prepared E.g., a multi-step synthesis of II which was active at 1-100 μ M against MAPKAP-K2, was given.

IT 754204-52-9P 754204-59-6P 754205-21-5P
754205-23-7P 754205-25-9P 754205-27-1P
754205-65-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[1,5-a]pyrimidines for treating or preventing protein kinase mediated disorders)

RN 754204-52-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-3-bromo-N7-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 754204-59-6 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-3-chloro-N7-(3-chloro-4-fluorophenyl)- (CA
INDEX NAME)

Relative stereochemistry.




RN 754205-21-5 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2-chlorophenyl)-3-iodo- (CA INDEX NAME)

Relative stereochemistry.



RN 754205-23-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(4-ethoxyphenyl)-3-iodo- (CA INDEX NAME)


Relative stereochemistry.




RN 754205-25-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(3-chloro-4-fluorophenyl)-3-iodo- (CA
INDEX NAME)

Relative stereochemistry.




RN 754205-27-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
3-bromo-N7-(3-chloro-4-fluorophenyl)-N5-3-piperidinyl- (CA INDEX NAME)

RN 754205-65-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(3-chloro-4-fluorophenyl)-3-(methylthio)-
(CA INDEX NAME)

Relative stereochemistry.




IT 754211-11-5P 754211-17-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of pyrazolo[1,5-a]pyrimidines for treating or preventing
protein kinase mediated disorders)


RN 754211-11-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3,5-dichloro-N-(3-chloro-4-fluorophenyl)-
(CA INDEX NAME)



RN 754211-17-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(3-chloro-4-fluorophenyl)-3-
(methylthio)- (CA INDEX NAME)



REFERENCE COUNT:


14

THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 6
 ACCESSION NUMBER: 2004:269996 CAPLUS Full-text
 DOCUMENT NUMBER: 140:303691
 TITLE: Preparation and pharmaceutical compositions of novel
 pyrazolopyrimidines as cyclin dependent kinase
 inhibitors
 INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.;
 Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil;
 Alvarez, Carmen S.; Chan, Tin-Yau; Knutson, Chad;
 Madison, Vincent; Fischmann, Thierry O.; Dillard,
 Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray
 Anthony; Park, Haengsoon
 PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026229	A2	20040401	WO 2003-US27491	20030903
WO 2004026229	A3	20040617		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2497544	A1	20040401	CA 2003-2497544	20030903
AU 2003298571	A1	20040408	AU 2003-298571	20030903
AU 2003298571	B2	20061019		
EP 1534712	A2	20050601	EP 2003-796321	20030903
EP 1534712	B1	20070516		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1701073	A	20051123	CN 2003-824701	20030903
JP 2006502184	T	20060119	JP 2004-537708	20030903
NZ 539161	A	20060526	NZ 2003-539161	20030903
AT 362474	T	20070615	AT 2003-796321	20030903
ES 2283868	T3	20071101	ES 2003-796321	20030903
ZA 2005001846	A	20050912	ZA 2005-1846	20050303
MX 2005002572	A	20050908	MX 2005-2572	20050304
HK 1071572	A1	20070713	HK 2005-104747	20050607
PRIORITY APPLN. INFO.:			US 2002-408029P	P 20020904
			WO 2003-US27491	W 20030903
OTHER SOURCE(S):	MARPAT 140:303691			
GI				



AB In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compds. I [R = (un)substituted aryl; R2 = halo, CN, (un)substituted alkyl, etc.; R3 = H, halo, (un)substituted-alkyl, -alkynyl, -aryl, etc.; R4 = H, halo or alkyl] as inhibitors of cyclin dependent kinases, methods of preparing such compds., pharmaceutical compns. containing one or more such compds., methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepared by substitution of 3-bromo-7-chloro-5-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidine (preparation given) with aniline. I exhibit excellent CDK inhibitory properties as demonstrated by II which possessed a IC50 value of 0.51 μ M in kinase activity assays.


IT 676366-27-1P 676366-28-2P 676366-29-3P
676366-33-9P 676366-34-0P 676366-35-1P
676366-42-0P 676366-51-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of pyrazolopyrimidines as cyclin dependent kinase inhibitors)


RN 676366-27-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]-, phenylmethyl ester (CA INDEX NAME)




RN 676366-28-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]-, phenylmethyl ester (CA INDEX NAME)




RN 676366-29-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-chloro-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-33-9 CAPLUS

CN Benzenesulfonic acid, 3-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 676366-34-0 CAPLUS

CN Benzenesulfonic acid, 4-[[3-bromo-5-(2-fluorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 676366-35-1 CAPLUS

CN Benzenesulfonic acid, 4-[(3-ethyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 676366-42-0 CAPLUS

CN Carbamic acid, [2-[[[4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl]sulfonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 676366-51-1 CAPLUS
 CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(2-methoxyethyl)- (CA INDEX NAME)




IT 676366-05-5P 676366-06-6P 676366-07-7P
 676366-08-8P 676366-09-9P 676366-10-2E
 676366-11-3P 676366-12-4P 676366-13-5E
 676366-14-6P 676366-15-7P 676366-16-8P
 676366-17-9P 676366-18-0P 676366-19-1P
 676366-20-4P 676366-21-5P 676366-22-6P
 676366-23-7P 676366-24-8P 676366-25-9P
 676366-26-0P 676366-30-6P 676366-31-7P
 676366-32-8P 676366-36-2P 676366-37-2P
 676366-38-4P 676366-39-5P 676366-40-8P
 676366-41-9P 676366-43-1P 676366-44-2P
 676366-45-3P 676366-46-4P 676366-47-5E
 676366-48-6P 676366-49-7P 676366-50-0E
 676366-52-2P 676366-53-3P 676366-54-4P
 676366-55-5P 676366-56-6P 676366-57-7P
 676366-58-8P 676366-59-9P 676366-60-2P
 676366-61-3P 676366-62-4P 676366-63-5P
 676366-64-6P 676366-65-7P 676366-66-8P
 676366-67-9P 676366-68-0P 676366-69-1P
 676366-70-4P 676366-71-5P 676366-72-6P
 676366-73-7P 676366-74-8P 676366-75-9P
 676366-76-0P 676366-77-1P 676366-78-2E
 676366-79-3P 676366-80-6P 676366-82-8E
 676366-83-9P 676366-84-0P 676366-85-1P
 676366-86-2P 676366-87-3P 676366-88-4P
 676366-89-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of pyrazolopyrimidines as cyclin dependent
 kinase inhibitors)


RN 676366-05-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-[4-
 (methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-06-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-phenyl-
(CA INDEX NAME)




RN 676366-07-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-chloro-5-(2-fluorophenyl)-N-phenyl-
(CA INDEX NAME)




RN 676366-08-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-chloro-5-(2-fluorophenyl)-N-[4-
(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-09-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-fluorophenyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-10-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-N-[4-(methylsulfonyl)phenyl]-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 676366-11-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(1-methylethyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-12-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(1-methylethyl)-N-phenyl- (CA INDEX NAME)




RN 676366-13-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(1,1-dimethylethyl)-N-phenyl- (CA INDEX NAME)




RN 676366-14-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-cyclopropyl-N-[4-(methylsulfonyl)phenyl]-5-phenyl- (CA INDEX NAME)




RN 676366-15-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methylethyl)-N-[4-(methylsulfonyl)phenyl]-5-phenyl- (CA INDEX NAME)




RN 676366-16-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(4-chlorophenyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-17-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2,3-dichlorophenyl)-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 676366-18-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-N-(3-chlorophenyl)-5-(2-methoxyphenyl)- (CA INDEX NAME)




RN 676366-19-1 CAPLUS

CN Phenol, 3-[[3-bromo-5-(2-methylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 676366-20-4 CAPLUS

CN Benzenemethanol, 5-[[3-bromo-5-(2,3-dichlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-2-chloro- (CA INDEX NAME)




RN 676366-21-5 CAPLUS

CN Benzenemethanol, 3-[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 676366-22-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-(3-methoxyphenyl)- (CA INDEX NAME)




RN 676366-23-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 676366-24-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-N-[4-(methanesulfonyl)phenyl]-5-phenyl- (CA INDEX NAME)




RN 676366-25-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(3-furanyl)-N-[4-(methanesulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-26-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-furanyl)-N-[4-(methanesulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-30-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-cyclohexyl-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-31-7 CAPLUS

CN Benzenesulfonic acid, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 676366-32-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-ethyl-N-[4-(methylsulfonyl)phenyl]-5-phenyl- (CA INDEX NAME)




RN 676366-36-2 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-propyl- (CA INDEX NAME)




RN 676366-37-3 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-ethyl- (CA INDEX NAME)




RN 676366-38-4 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N,N-dimethyl- (CA INDEX NAME)




RN 676366-39-5 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 676366-40-8 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 676366-41-9 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-methyl- (CA INDEX NAME)




RN 676366-43-1 CAPLUS

CN Benzenesulfonamide, N-(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 676366-44-2 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 676366-45-3 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(3-hydroxypropyl)- (CA INDEX NAME)




RN 676366-46-4 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-phenyl- (CA INDEX NAME)



RN 676366-47-5 CAPLUS


CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-4-pyridinyl- (CA INDEX NAME)




RN 676366-48-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl]sulfonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 676366-49-7 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-cyclopentyl- (CA INDEX NAME)




RN 676366-50-0 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(2-hydroxy-1-methylethyl)- (CA INDEX NAME)




RN 676366-52-2 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 676366-53-3 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 676366-54-4 CAPLUS


CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 676366-55-5 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 676366-56-6 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N,N-bis(2-hydroxyethyl)- (CA INDEX NAME)




RN 676366-57-7 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[3-(dimethylamino)-2,2-dimethylpropyl]- (CA INDEX NAME)




RN 676366-58-8 CAPLUS

CN Ethanesulfonic acid, 2-[[[4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl]sulfonyl]amino]- (CA INDEX NAME)




RN 676366-59-9 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (CA INDEX NAME)




RN 676366-60-2 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]- (CA INDEX NAME)




RN 676366-61-3 CAPLUS

CN Glycine, N-[[4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)




RN 676366-62-4 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)



RN 676366-63-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-N-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5-phenyl- (CA INDEX NAME)



RN 676366-64-6 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[(1R)-1-(hydroxymethyl)-2-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 676366-65-7 CAPLUS


CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[(1S)-1-(hydroxymethyl)-2-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 676366-66-8 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-cyclohexyl- (CA INDEX NAME)



RN 676366-67-9 CAPLUS


CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)




RN 676366-68-0 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 676366-69-1 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[3-(2-oxo-1-pyrrolidiny)propyl]- (CA INDEX NAME)



RN 676366-70-4 CAPLUS


CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)



RN 676366-71-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl]sulfonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 676366-72-6 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[[[4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl]sulfonyl]amino]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 676366-73-7 CAPLUS

CN Benzenesulfonamide, 3-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 676366-74-8 CAPLUS

CN Benzenesulfonamide, 3-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(2-hydroxypropyl)- (CA INDEX NAME)




RN 676366-75-9 CAPLUS

CN Benzenesulfonamide, 4-[[3-bromo-5-(2-fluorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 676366-76-0 CAPLUS

CN Benzenesulfonamide, N-[2-(dimethylamino)ethyl]-4-[(3-ethyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 676366-77-1 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]-, (2S)- (CA

INDEX NAME)

Absolute stereochemistry.




RN 676366-78-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
3-bromo-N5-cyclohexyl-N7-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)

RN 676366-79-3 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 676366-80-6 CAPLUS

CN 1-Butanol, 2-[[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]-3-methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 676366-82-8 CAPLUS


CN 1-Butanol, 2-[[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 676366-83-9 CAPLUS

CN 2-Piperidinemethanol, 1-[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]- (CA INDEX NAME)




RN 676366-84-0 CAPLUS

CN 2-Piperidineethanol, 1-[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]- (CA INDEX NAME)



RN 676366-85-1 CAPLUS


CN Cyclopentanemethanol, 1-[[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]- (CA INDEX NAME)



RN 676366-86-2 CAPLUS

CN Cyclohexanemethanol, 2-[[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]-, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 676366-87-3 CAPLUS


CN Cyclohexanemethanol, 2-[[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 676366-88-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-N-[4-(methylsulfonyl)phenyl]-5-(4-piperidinyl)- (CA INDEX NAME)



RN 676366-89-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-N-[4-(methylsulfonyl)phenyl]-5-(3-piperidinyl)- (CA INDEX NAME)



L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:61837 CAPLUS Full-text

DOCUMENT NUMBER: 146:156236

TITLE: Cellular cholesterol absorption modifiers, and their therapeutic use

INVENTOR(S): Gardiner, Elisabeth M.; Duron, Sergio G.; Massari, Mark E.; Severance, Daniel L.; Semple, Joseph E.

PATENT ASSIGNEE(S): Kalypsys, Inc., USA

SOURCE: PCT Int. Appl., 300pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007008541	A2	20070118	WO 2006-US26242	20060705
WO 2007008541	A3	20070726		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.:
 US 2005-697659P P 20050708
 US 2005-697686P P 20050708
 US 2005-697814P P 20050708
 US 2005-727646P P 20051017
 US 2006-782303P P 20060313


OTHER SOURCE(S): MARPAT 146:156236

AB The invention discloses compds. and methods useful as inhibitors of cholesterol absorption for the treatment or prevention of vascular disease and atherosclerosis.

IT 920529-77-7 920529-78-8 920529-79-9
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cholesterol absorption modifiers and therapeutic use)


RN 920529-77-7 CAPLUS

CN 1,3-Benzenediamine, N3-[5-[4-(dimethylamino)phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 920529-78-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 920529-79-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-(4-methyl-2-thienyl)-N-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



L8 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:1170528 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 148:54982
 TITLE: Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2
 AUTHOR(S): Paruch, Kamil; Dwyer, Michael P.; Alvarez, Carmen; Brown, Courtney; Chan, Tin-Yau; Doll, Ronald J.; Keertikar, Kerry; Knutson, Chad; McKittrick, Brian; Rivera, Jocelyn; Rossman, Randall; Tucker, Greg; Fischmann, Thierry O.; Hruza, Alan; Madison, Vincent; Nomeir, Amin A.; Wang, Yaolin; Lees, Emma; Parry, David; Sgambellone, Nicole; Seghezzi, Wolfgang; Schultz, Lesley; Shanahan, Fran; Wiswell, Derek; Xu, Xiaoying; Zhou, Quiao; James, Ray A.; Paradkar, Vidyadhar M.; Park, Haengsoon; Rokosz, Laura R.; Stauffer, Tara M.; Guzi, Timothy J.
 CORPORATE SOURCE: Schering-Plough Research Institute, Kenilworth, NJ, 07033, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(22), 6220-6223
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




I

AB Properly substituted pyrazolo[1,5-a]pyrimidines are potent and selective CDK2 inhibitors. I is orally available and showed efficacy in a mouse A2780 xenograft model.

IT 576366-05-5P 959995-71-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2)


RN 676366-05-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 959995-71-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-fluorophenyl)-N-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:566890 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 147:180515

TITLE: Virtual Screening Studies to Design Potent CDK2-Cyclin A Inhibitors

AUTHOR(S): Vadivelan, S.; Sinha, Barij Nayan; Irudayam, Sheeba Jem; Jagarlapudi, Sarma A. R. P.

CORPORATE SOURCE: GVK Biosciences Pvt. Ltd., Hyderabad, 500037, India

SOURCE: Journal of Chemical Information and Modeling (2007), 47(4), 1526-1535

PUBLISHER: CODEN: JCISD8; ISSN: 1549-9596 American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The cell division cycle is controlled by cyclin-dependent kinases (CDK), which consist of a catalytic subunit (CDK1-CDK8) and a regulatory subunit (cyclin A-H). Pharmacophore anal. indicates that the best inhibitor model consists of (1) two hydrogen bond acceptors, (2) one hydrogen bond donor, and (3) one hydrophobic feature. The HypoRefine pharmacophore model gave an enrichment factor of 1.31 and goodness of fit score of 0.76. Docking studies were carried out to explore the structural requirements for the CDK2-cyclin A inhibitors and to construct highly predictive models for the design of new inhibitors. Docking studies demonstrate the important role of hydrogen bond and hydrophobic interactions in determining the inhibitor-receptor binding affinity. The validated pharmacophore model is further used for retrieving the most active hits/lead from a virtual library of mols. Subsequently, docking studies were performed on the hits, and novel series of potent leads were suggested based on the interaction energy between CDK2-cyclin A and the putative inhibitors.

IT 771499-44-6 771499-50-4 771499-95-7
 771500-00-6 771503-67-4 771504-46-2
 771504-52-0 771505-96-5 771506-54-8
 771506-60-6 771507-72-3 771508-51-1
 845895-93-4


RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)

(virtual screening studies to design CDK2-cyclin A inhibitors)

RN 771499-44-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771499-50-4 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-bromopyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.




RN 771499-95-7 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-([3-(1-methylethyl)-5-(2-methylpropoxy)pyrazolo[1,5-a]pyrimidin-7-yl]amino)- (CA INDEX NAME)



RN 771500-00-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methylethyl)-5-(2-methylpropoxy)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 771503-67-4 CAPLUS


CN Benzenesulfonamide, 4-[[5-[[trans-4-(diethylamino)cyclohexyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.



RN 771504-46-2 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(3-aminocyclohexyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771504-52-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)oxy]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.




RN 771505-96-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,

N5-(trans-4-aminocyclohexyl)-3-bromo-N7-[4-(phenylsulfonyl)phenyl]- (CA
INDEX NAME)


Relative stereochemistry.



RN 771506-54-8 CAPLUS

CN Benzenesulfonamide, 4-[[5-[[trans-4-(ethylamino)cyclohexyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771506-60-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-[[trans-4-aminocyclohexyl]amino]-3-chloropyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771507-72-3 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-cyclopentylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.




RN 771508-51-1 CAPLUS
 CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-bromopyrazolo[1,5-a]pyrimidin-7-yl]amino]-2-chloro-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.



RN 845895-93-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(trans-4-aminocyclohexyl)-3-chloro-N7-[4-(2-thienylsulfonyl)phenyl]- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:1291827 CAPLUS Full-text
 DOCUMENT NUMBER: 146:176174
 TITLE: Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints
 AUTHOR(S): Marcou, Gilles; Rognan, Didier
 CORPORATE SOURCE: Bioinformatics of the Drug, UMR 7175 CNRS-ULP (Universite Louis Pasteur- Strasbourg I), Illkirch, F-67400, Fr.
 SOURCE: Journal of Chemical Information and Modeling (2007), 47(1), 195-207
 CODEN: JCISD8; ISSN: 1549-9596
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Protein-ligand interaction fingerprints have been used to postprocess docking poses of three ligand data sets: a set of 40 low-mol.-weight compds. from the Protein Data Bank, a collection of 40 scaffolds from pharmaceutically relevant protein ligands, and a database of 19 scaffolds extracted from true cdk2 inhibitors seeded in 2230 scaffold decoys. Four popular docking tools (FlexX, Glide, Gold, and Surflex) were used to generate poses for ligands of the three data sets. In all cases, scoring by the similarity of interaction fingerprints to a given reference was statistically superior to conventional scoring functions in posing low-mol.-weight fragments, predicting protein-bound scaffold coordinates according to the known binding mode of related ligands, and screening a scaffold library to enrich a hit list in true cdk2-targeted scaffolds.

IT 771498-73-8
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (optimizing fragment and scaffold docking by use of mol. interaction fingerprints)

RN 771498-73-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)





REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:167936 CAPLUS Full-text
 DOCUMENT NUMBER: 144:254145
 TITLE: Preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
 INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.
 PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S. Ser. No. 653,776.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060041131	A1	20060223	US 2005-244772	20051006
US 7205308	B2	20070417		
US 20040106624	A1	20040603	US 2003-653776	20030903
US 7067661	B2	20060627		
US 20060178371	A1	20060810	US 2006-395676	20060331
US 20070072880	A1	20070329	US 2006-542833	20061004
CA 2624822	A1	20070419	CA 2006-2624822	20061004
WO 2007044420	A1	20070419	WO 2006-US38838	20061004
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1934224	A1	20080625	EP 2006-816244	20061004
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
MX 2008004663	A	20080417	MX 2008-4663	20080407
CN 101321757	A	20081210	CN 2006-80045402	20080603
PRIORITY APPLN. INFO.:				
			US 2002-408029P	P 20020904
			US 2003-653776	A2 20030903
			US 2005-244772	A2 20051006
			WO 2006-US38838	W 20061004
OTHER SOURCE(S): CASREACT 144:254145; MARPAT 144:254145				
GI				



AB The title compds. I [R = aryl optionally substituted with one or more heteroaryl; R2 = alkyl, cycloalkyl, CF3, etc.; R3 = H, halo, alkyl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases, were prepared. Thus, reacting II (preparation given) with 4-methylsulfonylaniline hydrochloride in the presence of iPr2NEt afforded 23% III. The compds. I were tested in in vitro cyclin E/CDK2 kinase assay (biol. data given for representative compds. I). The invention also provides pharmaceutical compns. containing one or more compds. I, methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compds. or pharmaceutical compns.


IT 676366-21-5 676366-22-6 676366-23-7
 676366-25-9 676366-26-0 676366-27-1
 676366-28-2 676366-30-6 676366-76-2
 676366-79-3 676366-80-6 676366-82-8
 676366-83-9 676366-84-0 676366-85-1
 676366-88-4 676366-89-5 1057251-70-3
 1057251-71-4

RL: PRPH (Prophetic)

(Preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors)


RN 676366-21-5 CAPLUS

CN Benzenemethanol, 3-[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 676366-22-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-(3-methoxyphenyl)- (CA INDEX NAME)




RN 676366-23-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 676366-25-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(3-furanyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-26-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-furanyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-27-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]-, phenylmethyl ester (CA INDEX NAME)




RN 676366-28-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]-, phenylmethyl ester (CA INDEX NAME)




RN 676366-30-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-cyclohexyl-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 676366-78-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, 3-bromo-N5-cyclohexyl-N7-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-79-3 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[3-bromo-7-[[4-

(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]-, (2R)- (CA
INDEX NAME)


Absolute stereochemistry.



RN 676366-80-6 CAPLUS

CN 1-Butanol, 2-[[[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]-3-methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 676366-82-8 CAPLUS


CN 1-Butanol, 2-[[[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 676366-83-9 CAPLUS

CN 2-Piperidinemethanol, 1-[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]- (CA INDEX NAME)




RN 676366-84-0 CAPLUS

CN 2-Piperidineethanol, 1-[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]- (CA INDEX NAME)




RN 676366-85-1 CAPLUS

CN Cyclopentanemethanol, 1-[[[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]- (CA INDEX NAME)




RN 676366-88-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-N-[4-(methylsulfonyl)phenyl]-5-(4-piperidinyl)- (CA INDEX NAME)



RN 676366-89-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-N-[4-(methylsulfonyl)phenyl]-5-(3-piperidinyl)- (CA INDEX NAME)




RN 1057251-70-3 CAPLUS

CN Cyclohexanemethanol, 2-[[[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]-,

(1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1057251-71-4 CAPLUS

CN Cyclohexanemethanol, 2-[[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]-,
(1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 676366-29-3P 676366-31-7P 676366-35-1P

676366-42-0P 676366-51-1P 877173-62-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors for treatment and prevention of diseases)


RN 676366-29-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-chloro-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-31-7 CAPLUS

CN Benzenesulfonic acid, 4-((3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino)- (CA INDEX NAME)




RN 676366-35-1 CAPLUS

CN Benzenesulfonic acid, 4-((3-ethyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino)- (CA INDEX NAME)




RN 676366-42-0 CAPLUS

CN Carbamic acid, [2-[[[4-((3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino)phenyl]sulfonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 676366-51-1 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 877173-62-1 CAPLUS

CN Benzenesulfonic acid, 3-[[3-bromo-5-(2-fluorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)



IT 676366-05-5P 676366-06-6P 676366-07-7P
 676366-08-8P 676366-09-9P 676366-10-2P
 676366-11-3P 676366-12-4P 676366-13-5P
 676366-14-6P 676366-15-7P 676366-16-8P


676366-17-9P 676366-18-0P 676366-19-1P
 676366-20-4P 676366-24-8P 676366-32-8P
 676366-33-9P 676366-36-2P 676366-37-3P
 676366-39-5P 676366-40-8P 676366-41-9P
 676366-43-1P 676366-44-2P 676366-45-3P
 676366-46-4P 676366-47-5P 676366-48-6P
 676366-49-7P 676366-50-0P 676366-52-2P
 676366-53-3P 676366-54-4P 676366-55-5P
 676366-56-6P 676366-57-7P 676366-58-8P
 676366-59-9P 676366-60-2P 676366-61-3P
 676366-62-4P 676366-63-5P 676366-64-6P
 676366-65-7P 676366-66-8P 676366-67-9P
 676366-68-0P 676366-69-1P 676366-70-4P
 676366-71-5P 676366-72-6P 676366-73-7P
 676366-74-8P 676366-75-9P 676366-76-0P
 676366-77-1P 877173-63-2P 877173-67-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors for treatment and prevention of diseases)


RN 676366-05-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-06-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-phenyl- (CA INDEX NAME)




RN 676366-07-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-chloro-5-(2-fluorophenyl)-N-phenyl- (CA INDEX NAME)




RN 676366-08-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-chloro-5-(2-fluorophenyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-09-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-fluorophenyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-10-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-N-[4-(methylsulfonyl)phenyl]-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 676366-11-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(1-methylethyl)-N-(4-(methylsulfonyl)phenyl)- (CA INDEX NAME)




RN 676366-12-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(1-methylethyl)-N-phenyl- (CA INDEX NAME)




RN 676366-13-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(1,1-dimethylethyl)-N-phenyl- (CA INDEX NAME)




RN 676366-14-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-cyclopropyl-N-[4-(methylsulfonyl)phenyl]-5-phenyl- (CA INDEX NAME)




RN 676366-15-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methylethyl)-N-[4-(methylsulfonyl)phenyl]-5-phenyl- (CA INDEX NAME)




RN 676366-16-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(4-chlorophenyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 676366-17-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2,3-dichlorophenyl)-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 676366-18-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-N-(3-chlorophenyl)-5-(2-methoxyphenyl)- (CA INDEX NAME)




RN 676366-19-1 CAPLUS

CN Phenol, 3-[[3-bromo-5-(2-methylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 676366-20-4 CAPLUS

CN Benzenemethanol, 5-[[3-bromo-5-(2,3-dichlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-2-chloro- (CA INDEX NAME)




RN 676366-24-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-N-[4-(methylsulfonyl)phenyl]-5-phenyl- (CA INDEX NAME)




RN 676366-32-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-ethyl-N-[4-(methylsulfonyl)phenyl]-5-phenyl- (CA INDEX NAME)




RN 676366-33-9 CAPLUS

CN Benzenesulfonic acid, 3-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 676366-36-2 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-propyl- (CA INDEX NAME)




RN 676366-37-3 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-ethyl- (CA INDEX NAME)




RN 676366-39-5 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 676366-40-8 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 676366-41-9 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-methyl- (CA INDEX NAME)




RN 676366-43-1 CAPLUS

CN Benzenesulfonamide, N-(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 676366-44-2 CAPLUS


CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 676366-45-3 CAPLUS
 CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(3-hydroxypropyl)- (CA INDEX NAME)



RN 676366-46-4 CAPLUS
 CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-phenyl- (CA INDEX NAME)




RN 676366-47-5 CAPLUS
 CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-4-pyridinyl- (CA INDEX NAME)




RN 676366-48-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl]sulfonyl]amino]-, 1,1-dimethylethyl ester
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 676366-49-7 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-cyclopentyl- (CA INDEX NAME)




RN 676366-50-0 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(2-hydroxy-1-methylethyl)- (CA INDEX NAME)




RN 676366-52-2 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 676366-53-3 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 676366-54-4 CAPLUS


CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 676366-55-5 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 676366-56-6 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N,N-bis(2-hydroxyethyl)- (CA INDEX NAME)




RN 676366-57-7 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[3-(dimethylamino)-2,2-dimethylpropyl]- (CA INDEX NAME)




RN 676366-58-8 CAPLUS

CN Ethanesulfonic acid, 2-[[[4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl]sulfonyl]amino]- (CA INDEX NAME)




RN 676366-59-9 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (CA INDEX NAME)




RN 676366-60-2 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]- (CA INDEX NAME)




RN 676366-61-3 CAPLUS

CN Glycine, N-[[4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)




RN 676366-62-4 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)



RN 676366-63-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-N-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-5-phenyl- (CA INDEX NAME)



RN 676366-64-6 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[(1R)-1-(hydroxymethyl)-2-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 676366-65-7 CAPLUS


CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[(1S)-1-(hydroxymethyl)-2-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 676366-66-8 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-cyclohexyl- (CA INDEX NAME)



RN 676366-67-9 CAPLUS


CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[(1-ethyl-2-pyrrolidiny)methyl]- (CA INDEX NAME)




RN 676366-68-0 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[2-(1-methyl-2-pyrrolidiny)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 676366-69-1 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[3-(2-oxo-1-pyrrolidiny)propyl]- (CA INDEX NAME)



RN 676366-70-4 CAPLUS


CN Benzenesulfonamide, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)



RN 676366-71-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl]sulfonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 676366-72-6 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[[[4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl]sulfonyl]amino]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 676366-73-7 CAPLUS

CN Benzenesulfonamide, 3-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 676366-74-8 CAPLUS

CN Benzenesulfonamide, 3-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-(2-hydroxypropyl)- (CA INDEX NAME)




RN 676366-75-9 CAPLUS

CN Benzenesulfonamide, 4-[[3-bromo-5-(2-fluorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 676366-76-0 CAPLUS

CN Benzenesulfonamide, N-[2-(dimethylamino)ethyl]-4-[(3-ethyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 676366-77-1 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[3-bromo-7-[[4-(methylsulfonyl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]-, (2S)- (CA


INDEX NAME)

Absolute stereochemistry.




RN 877173-63-2 CAPLUS

CN Benzenesulfonic acid, 4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, 2,2-dimethylhydrazide (CA INDEX NAME)




RN 877173-67-6 CAPLUS


CN Benzenesulfonamide, N-(2-aminoethyl)-4-[(3-bromo-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




IT 877173-85-8P 877173-86-9P 877173-87-0P
 877173-88-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of novel pyrazolopyrimidines as cyclin dependent kinase
 inhibitors for treatment and prevention of diseases)
 RN 877173-88-8 CAPLUS
 CN 1,3-Benzenediamine, N3-(3-bromopyrazolo[1,5-a]pyrimidin-7-yl)-N1,N1-
 dimethyl- (CA INDEX NAME)




RN 877173-86-9 CAPLUS
 CN Phenol, 4-[(3-bromopyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)



RN 877173-87-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[3-bromo-7-[(3-(dimethylamino)phenyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]-,
 1,1-dimethylethyl ester (CA INDEX NAME)



RN 877173-88-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[3-bromo-7-[[4-(1H-imidazol-1-yl)phenyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]-, 1,1-dimethylethyl ester
 (CA INDEX NAME)



L8 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:826276 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:391311

TITLE: A Novel Computational Analysis of Ligand-Induced Conformational Changes in the ATP Binding Sites of Cyclin Dependent Kinases

AUTHOR(S): Subramanian, Jyothi; Sharma, Somesh; B-Rao, Chandrika
 CORPORATE SOURCE: Cheminformatics, Nicholas Piramal Research Centre, Mumbai, 400063, India

SOURCE: Journal of Medicinal Chemistry (2006), 49(18), 5434-5441

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Protein kinases in general are known to be very flexible macromols. In this article, the conformational plasticity of the ATP binding site in cyclin dependent kinases is analyzed. Movement of the two lysine residues lining the ATP binding site are shown to play a major role in the conformational variability of the site. Linear models are developed to identify and quantify ligand properties that maximally influence the lysine side chain conformations. A few simple properties of the ligands are shown to account for more than 70% of the variation in the lysine conformations. The results are validated using test data and mol. simulation studies. Illustrative applications of the results of this anal. to finding the appropriate crystal structure for mol. docking and binding mode predictions of novel ligands are provided. This work provides a new approach to quantify ligand-induced conformational changes in the active sites of flexible proteins and to find the appropriate crystal structure for docking novel ligands.

IT 911302-31-3

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ligand; novel computational anal. of ligand-induced conformational changes in the ATP binding sites of cyclin dependent kinases)

RN 911302-31-3 CAPLUS
 CN Benzenesulfonamide, 4-[[5-[(4-aminocyclohexyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:86349 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:253677

TITLE: Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2

AUTHOR(S): Williamson, Douglas S.; Parratt, Martin J.; Bower, Justin F.; Moore, Jonathan D.; Richardson, Christine M.; Dokurno, Pawel; Cansfield, Andrew D.; Francis, Geraint L.; Hebdon, Richard J.; Howes, Rob; Jackson, Philip S.; Lockie, Andrea M.; Murray, James B.; Nunns, Claire L.; Powles, Jenifer; Robertson, Alan; Surgenor, Allan E.; Torrance, Christopher J.

CORPORATE SOURCE: Granta Park, Vernalis (R&D) Ltd., Cambridge, CB1 6GB, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(4), 863-867

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:253677

AB The protein structure guided design of a series of pyrazolo[1,5-a]pyrimidines with high potency for human cyclin-dependent kinase 2 (CDK2) is described. Some examples were shown to inhibit the growth of human colon tumor cells, were equipotent for CDK1 and were selective against GSK-3 β and other kinases.

IT 771499-44-6P 771499-50-4P 771499-95-7P
 771500-80-6P 771503-67-4P 771504-46-2P
 771504-52-0P 771505-96-5P 771506-54-8P
 771506-60-6P 771507-72-3P 771508-51-1P
 845895-93-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(structure-guided design of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors)

RN 771499-44-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771499-50-4 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-bromopyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.




RN 771499-95-7 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-[[3-(1-methylethyl)-5-(2-methylpropoxy)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 771500-00-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methylethyl)-5-(2-methylpropoxy)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 771503-67-4 CAPLUS


CN Benzenesulfonamide, 4-[[5-[[trans-4-(diethylamino)cyclohexyl]amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.



RN 771504-46-2 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(3-aminocyclohexyl)amino]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 771504-52-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)oxy]-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771505-96-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(trans-4-aminocyclohexyl)-3-bromo-N7-[4-(phenylsulfonyl)phenyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 771506-54-8 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-(ethylamino)cyclohexyl]amino)-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)

(NAME)


Relative stereochemistry.



RN 771506-60-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-chloropyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771507-72-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-cyclopentylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 771508-51-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-bromopyrazolo[1,5-a]pyrimidin-7-yl]amino]-2-chloro-N,N-dimethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 845895-93-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-3-chloro-N7-[4-(2-thienylsulfonyl)phenyl]- (CA INDEX NAME)

Relative stereochemistry.



IT 771499-17-3P 771499-34-4P 771502-21-7P


771505-91-0P 771503-26-3P 845895-96-7P

845895-98-9P 845895-99-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(structure-guided design of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors)


RN 771499-17-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-3-(1-methylethyl)-N-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771499-34-4 CAPLUS

CN Benzenesulfonamide, 4-[(5-chloro-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl)amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771502-21-7 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-chloropyrazolo[1,5-a]pyrimidin-7-yl)amino]-N,N-dimethyl- (CA INDEX NAME)




RN 771505-91-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-chloro-N-[4-(phenylsulfonyl)phenyl]- (CA INDEX NAME)




RN 771509-26-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3,5-dichloro-N-[4-(2-thienylsulfonyl)phenyl]- (CA INDEX NAME)




RN 845895-96-7 CAPLUS

CN Benzenesulfonamide, 4-[(5-chloro-3-cyclopentylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845895-98-9 CAPLUS

CN Benzenesulfonamide, 4-[(3,5-dichloropyrazolo[1,5-a]pyrimidin-7-yl)amino]-
N,N-dimethyl- (CA INDEX NAME)

RN 845895-99-0 CAPLUS

CN Benzenesulfonamide, 4-[(3-bromo-5-chloropyrazolo[1,5-a]pyrimidin-7-yl)amino]-2-chloro-N,N-dimethyl- (CA INDEX NAME)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:780706 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:296043

TITLE: Preparation of pyrazolo[1,5-a]pyrimidine derivs. as
kinase inhibitorsINVENTOR(S): Kataoka, Kenichiro; Kosugi, Tomomi; Imai, Minoru;
Mitchell, Dale Robert; Simpson, Donald James; Church,
Nicola Jane; Suzuki, Naotaka; Yamakoshi, Yuko

PATENT ASSIGNEE(S): Teijin Pharma Limited, Japan

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004081013	A1	20040923	WO 2004-JP3247	20040311
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004220212	A1	20040923	AU 2004-220212	20040311
CA 2518743	A1	20040923	CA 2004-2518743	20040311
EP 1608651	A1	20051228	EP 2004-719626	20040311
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
CN 1784410	A	20060607	CN 2004-80012366	20040311
JP 2006523219	T	20061012	JP 2006-507665	20040311
US 20060205743	A1	20060914	US 2005-548668	20050909
PRIORITY APPLN. INFO.:			GB 2003-5559	A 20030311
			WO 2004-JP3247	A 20040311
OTHER SOURCE(S):	MARPAT 141:296043			
GI				



AB Title compds. I [R1-2, R4 = H; R3 = alk(en/yn)yl, cycloalkyl, aryl, etc.; R5 = alk(en/yn)yl, cycloalkyl, aryl, etc.; R6 = H, alk(en/yn)yl, cycloalkyl, etc.] are prepared. For instance, II is prepared in several steps from 5,7-dichloropyrazolo[1,5-a]pyrimidine. All example compds. exhibited MAPKAPK-2 kinase activity (data given). I are useful for the treatment of kinase

mediated disorders, such as inflammation, autoimmune disorders, destructive bone disorder, cancer and tumor growth.

IT 761452-56-6P 761452-57-7P 761452-59-9P
 761452-60-2P 761452-62-4P 761452-63-5P
 761452-64-6P 761452-65-7P 761452-66-8P
 761452-68-0P 761452-69-1P 761452-70-4P
 761452-71-5P 761452-72-6P 761452-73-7P
 761452-74-8P 761452-77-1P 761452-78-2P
 761452-79-3P 761452-80-6P 761452-84-0P
 761452-86-2P 761452-87-3P 761452-88-4P
 761452-89-5P 761452-90-8P 761452-92-0P
 761452-93-1P 761452-94-2P 761452-95-3P
 761452-96-4P 761452-97-5P 761452-98-6P
 761452-99-7P 761453-01-4P 761453-02-5P
 761453-04-7P 761453-06-9P 761453-07-0P
 761453-08-1P 761453-11-6P 761453-12-7P
 761453-13-8P 761453-14-9P 761453-15-0P
 761453-16-1P 761453-17-2P 761453-18-3P
 761453-19-4P 761453-20-7P 761453-21-8P
 761453-23-0P 761453-24-1P 761453-25-2P
 761453-26-3P 761453-27-4P 761453-28-5P
 761453-29-6P 761453-30-9P 761453-31-0P
 761453-32-1P 761453-33-2P 761453-34-3P
 761453-35-4P 761453-36-5P 761453-37-6P
 761453-38-7P 761453-39-8P 761453-41-2P
 761453-42-3P 761453-43-4P 761453-44-5P
 761453-45-6P 761453-46-7P 761453-47-8P
 761453-48-9P 761453-49-0P 761453-50-3P
 761453-51-4P 761453-52-5P 761453-53-6P
 761453-54-7P 761453-55-8P 761453-56-9P
 761453-57-0P 761453-58-1P 761453-59-2P
 761453-62-7P 761453-63-8P 761453-64-9P
 761453-66-1P 761453-67-2P 761453-68-3P
 761453-69-4P 761453-70-7P 761453-71-8P
 761453-72-9P 761453-73-0P 761453-74-1P
 761453-75-2P 761453-76-3P 761453-77-4P
 761453-78-5P 761453-79-6P 761453-80-9P
 761453-81-0P 761453-82-1P 761453-83-2P
 761453-84-3P 761453-85-4P 761453-86-5P
 761453-87-6P 761453-88-7P 761453-89-8P
 761453-90-1P 764656-36-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[1,5-a]pyrimidine derivs. as kinase inhibitors)

RN 761452-56-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
 N5-(trans-4-aminocyclohexyl)-N7-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-57-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(3,4-dichlorophenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-59-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(3-chloro-4-methoxyphenyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 761452-60-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(3-chloro-4-methylphenyl)- (CA INDEX NAME)

NAME)


Relative stereochemistry.



RN 761452-62-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2-methylphenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-63-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-phenyl- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-64-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(3-chlorophenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-65-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(4-chlorophenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-66-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2-chlorophenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-68-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-[4-(dimethylamino)phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-69-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(4-fluorophenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-70-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(4-methoxyphenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-71-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-[3-(dimethylamino)phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-72-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-73-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(4-phenoxyphenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-74-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2,4-difluorophenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-77-1 CAPLUS

CN Acetamide, N-[trans-4-[[7-[(3-chloro-4-fluorophenyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-78-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(trans-4-aminocyclohexyl)-N7-[4-(methylthio)phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-79-3 CAPLUS

CN Methanesulfonamide, N-[trans-4-[[7-[(3-chloro-4-fluorophenyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-80-6 CAPLUS

CN Benamide, N-[trans-4-[[7-[(3-chloro-4-fluorophenyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-84-0 CAPLUS

CN Benzonitrile, 3-[[5-[(trans-4-aminocyclohexyl)amino]pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-86-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(trans-4-aminocyclohexyl)-N7-[4-(1,1-dimethylethyl)phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-87-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(4-ethoxyphenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-88-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(4-propylphenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-89-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-90-8 CAPLUS

CN Urea, N-[trans-4-[[7-[(3-chloro-4-fluorophenyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]cyclohexyl]-N'-methyl- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-92-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(trans-4-aminocyclohexyl)-N7-(3-iodophenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-93-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(trans-4-aminocyclohexyl)-N7-[4-(4-chlorophenoxy)phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-94-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-[4-[3-(trifluoromethyl)phenoxy]phenyl]-
(CA INDEX NAME)


Relative stereochemistry.



RN 761452-95-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(3,4-dimethylphenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-96-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(3-methylphenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-97-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2,6-dimethylphenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-98-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(3-phenoxyphenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761452-99-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2-methoxyphenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-01-4 CAPLUS


CN Urea, N-[trans-4-[[7-[(3-chloro-4-fluorophenyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]cyclohexyl]-N'-phenyl- (CA INDEX NAME)

Relative stereochemistry.



RN 761453-02-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 761453-04-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-06-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2-ethoxyphenyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 761453-07-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 761453-08-1 CAPLUS

CN Thiourea, N-[trans-4-[[7-[(3-chloro-4-fluorophenyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]cyclohexyl]-N'-methyl- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-11-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2,4-dichlorophenyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 761453-12-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(3-aminocyclohexyl)-N7-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)



RN 761453-13-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(3-methoxyphenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-14-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-[3-(trifluoromethoxy)phenyl]- (CA INDEX
NAME)


Relative stereochemistry.



RN 761453-15-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-[3-(phenylmethoxy)phenyl]- (CA INDEX
NAME)


Relative stereochemistry.



RN 761453-16-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(3-ethoxyphenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-17-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2-fluorophenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-18-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2,3-dichlorophenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-19-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2,5-dichlorophenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-20-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2,6-dichlorophenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-21-8 CAPLUS


CN Phenol, 4-[[5-[(trans-4-aminocyclohexyl)amino]pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.




RN 761453-23-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-(3-amino-1-piperidinyl)-N-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)




RN 761453-24-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-3-pyrrolidinyl- (CA INDEX NAME)



RN 761453-25-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-3-piperidinyl- (CA INDEX NAME)



RN 761453-26-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2,5-dimethylphenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-27-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2,3-dimethylphenyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 761453-28-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(4-aminobutyl)-N7-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)




RN 761453-29-6 CAPLUS

CN Guanidine, N-[4-[[7-[(3-chloro-4-fluorophenyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]cyclohexyl]-N'-cyano- (CA INDEX NAME)




RN 761453-30-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(2-aminoethyl)-N7-(3-chloro-4-fluorophenyl)-N-methyl- (CA INDEX NAME)




RN 761453-31-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(3-chloro-4-fluorophenyl)-5-(1-piperazinyl)- (CA INDEX NAME)




RN 761453-32-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-(3-amino-1-pyrrolidinyl)-N-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)



RN 761453-36-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[2-(methylamino)ethyl]- (CA INDEX NAME)



RN 761453-37-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-(methylamino)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 761453-38-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-4-piperidinyl- (CA INDEX NAME)



RN 761453-39-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-(trans-4-(ethylamino)cyclohexyl)- (CA
INDEX NAME)


Relative stereochemistry.



RN 761453-41-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-(ethylamino)cyclohexyl)-N7-[2-chloro-4-(trifluoromethyl)phenyl]- (CA
INDEX NAME)


Relative stereochemistry.



RN 761453-42-3 CAPLUS

CN Benzonitrile, 2-[(5-[(trans-4-aminocyclohexyl)amino]pyrazolo[1,5-a]
pyrimidin-7-yl)amino]- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-43-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
 N5-(trans-4-aminocyclohexyl)-N7-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 761453-44-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
 N5-(3-aminopropyl)-N7-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)




RN 761453-45-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-(4-amino-1-piperidinyl)-N-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)



RN 761453-46-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(2-methoxyphenyl)-N5-3-piperidinyl- (CA INDEX NAME)

RN 761453-47-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-methoxyphenyl)-N5-3-piperidinyl- (CA INDEX NAME)

RN 761453-48-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-[3-(phenylmethoxy)phenyl]-N5-3-piperidinyl- (CA INDEX NAME)



RN 761453-49-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2-chloro-5-methoxyphenyl)- (CA INDEX
NAME)


Relative stereochemistry.



RN 761453-50-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-[2-(1-methylethenyl)phenyl]- (CA INDEX
NAME)


Relative stereochemistry.



RN 761453-51-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2-iodophenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-52-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2-bromophenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-53-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2,3,4-trimethoxyphenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-54-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(4-butoxyphenyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 761453-55-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-ethoxyphenyl)-N5-3-piperidinyl- (CA INDEX NAME)



RN 761453-56-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N7-(4-iodophenyl)-N5-3-piperidinyl-
(CA INDEX NAME)



RN 761453-57-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-[2-chloro-4-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)


Relative stereochemistry.



RN 761453-58-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2-chloro-4-fluorophenyl)- (CA INDEX
NAME)


Relative stereochemistry.



RN 761453-59-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2,6-difluorophenyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-62-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(2-fluoro-4-methoxyphenyl)- (CA INDEX
NAME)


Relative stereochemistry.



RN 761453-63-8 CAPLUS

CN Pyr azolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-[2-fluoro-4-(1-methylethoxy)phenyl]- (CA
INDEX NAME)


Relative stereochemistry.



RN 761453-64-9 CAPLUS

CN Pyr azolo[1,5-a]pyrimidine-5,7-diamine,
N5-(trans-4-aminocyclohexyl)-N7-(4-methoxy-2-methylphenyl)- (CA INDEX
NAME)

Relative stereochemistry.




RN 761453-66-1 CAPLUS

CN Pyr azolo[1,5-a]pyrimidine-5,7-diamine,
N5-(2-aminoethyl)-N7-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)

yl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 761453-70-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-[(phenylmethyl)amino]cyclohexyl]-
(CA INDEX NAME)


Relative stereochemistry.



RN 761453-71-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-[(2-phenylethyl)amino]cyclohexyl]-
(CA INDEX NAME)

Relative stereochemistry.




RN 761453-72-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-[[3-(4-methoxyphenyl)-2-propen-1-yl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 761453-73-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-[[3-[4-(dimethylamino)phenyl]-2-propen-1-yl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 761453-74-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-[(3-phenylpropyl)amino]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-75-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-(pentylamino)cyclohexyl]- (CA
INDEX NAME)


Relative stereochemistry.



RN 761453-76-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-
[(cyclohexylmethyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 761453-77-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,

N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-[(3-furanyl)methyl]amino]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-78-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-(3-
furanylmethyl)amino]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-79-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-(3-
thienylmethyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 761453-80-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
 N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-[(2-ethylbutyl)amino]cyclohexyl]-
 (CA INDEX NAME)

Relative stereochemistry.




RN 761453-81-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
 N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-[(4-phenylbutyl)amino]cyclohexyl]-
 (CA INDEX NAME)

Relative stereochemistry.



RN 761453-82-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
 N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-[(5-phenylpentyl)amino]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-83-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N5-[trans-4-[[3-(4-bromophenyl)-2-propen-1-yl]amino]cyclohexyl]-N7-(3-
chloro-4-fluorophenyl)- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 761453-84-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-(cyclohexylamino)cyclohexyl]-
(CA INDEX NAME)


Relative stereochemistry.



RN 761453-85-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-[(1-methylethyl)amino]cyclohexyl]-
(CA INDEX NAME)


Relative stereochemistry.



RN 761453-86-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-[(1-methyl-4-
piperidiny]amino]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 761453-87-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-[[2-(dimethylamino)-1-
methylethyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 761453-88-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-cyclohexyl-N7-(4-ethoxyphenyl)-
(CA INDEX NAME)




RN 761453-89-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-cyclohexyl-N7-(3-iodophenyl)-
(CA INDEX NAME)



RN 761453-90-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-cyclohexyl-N7-(2-fluorophenyl)-
(CA INDEX NAME)



RN 764656-38-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine,
N7-(3-chloro-4-fluorophenyl)-N5-[trans-4-(4-
phenylcyclohexyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




IT 761453-91-2P 761453-92-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of pyrazolo[1,5-a]pyrimidine derivs. as kinase inhibitors)


RN 761453-91-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(2-methylphenyl)- (CA INDEX
NAME)



RN 761453-92-3 CAPLUS



CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(2,6-dichlorophenyl)- (CA
INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1995:777657 CAPLUS Full-text
 DOCUMENT NUMBER: 123:169666
 ORIGINAL REFERENCE NO.: 123:30299a,30302a
 TITLE: pyrazolo[1,5-a]pyrimidine derivatives and their use as
 angiotensin antagonists
 INVENTOR(S): Ruehter, Gerd; Schotten, Theo; Stenzel, Wolfgang;
 Paal, Michael
 PATENT ASSIGNEE(S): Beiersdorf-Lilly GmbH, Germany
 SOURCE: Eur. Pat. Appl., 63 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 628559	A1	19941214	EP 1994-304104	19940607
EP 628559	B1	20020403		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5571813	A	19961105	US 1994-254803	19940606
ES 2174863	T3	20021116	ES 1994-304104	19940607
CA 2125458	A1	19941211	CA 1994-2125458	19940608
JP 07002860	A	19950106	JP 1994-127441	19940609
US 5602136	A	19970211	US 1995-451586	19950526
US 5602137	A	19970211	US 1995-451799	19950526
PRIORITY APPLN. INFO.:			EP 1993-304513	A 19930610
			US 1994-254803	A3 19940606
OTHER SOURCE(S):	CASREACT 123:169666; MARPAT 123:169666			
GI				



- AB Fused pyrimidines I (R¹-R³ = H, alkyl, etc.; A, B = methine, nitrogen; AB together form pyrazolo, triazolo, imidazo group; X = oxygen, sulfur, nitrogen; A¹, A² = arylene; n = integer; Y = alkyl, alkoxy, alkylthio, etc.) were disclosed as angiotensin antagonists. I are selected from the group of pyrazolo[1,5-a]pyrimidines, 1,2,4-triazolo[1,5-a]pyrimidines, or imidazo[1,5-a]pyrimidines. A prepared example compound is 5-ethyl-N-methyl-N-[(1H-tetrazol-5-yl)biphenyl-4-yl]methylpyrazolo[1,5-a]pyrimidin-7-amine (II).
- IT 167371-82-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrazolo[1,5-a]pyrimidine derivs. angiotensin antagonists)
- RN 167371-82-6 CAPLUS
- CN Benzenesulfonic acid, 2-[[[4-[(5-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl]amino]carbonyl]- (CA INDEX NAME)




- IT 167371-71-3P 167371-74-6P 167371-79-1P
 167371-80-4P 167372-11-4P 167372-34-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrazolo[1,5-a]pyrimidine derivs. angiotensin antagonists)
- RN 167371-71-3 CAPLUS
- CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[(5-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 167371-74-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid,
4'-[(5-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, ethyl ester (CA INDEX
NAME)




RN 167371-79-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-ethyl-N-(4-nitrophenyl)- (CA INDEX
NAME)




RN 167371-80-4 CAPLUS

CN 1,4-Benzenediamine, N1-(5-ethylpyrazolo[1,5-a]pyrimidin-7-yl)- (CA INDEX
NAME)



RN 167372-11-4 CAPLUS


CN Benzeneacetonitrile, 4-[(5-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-
 α -phenyl- (CA INDEX NAME)



RN 167372-34-1 CAPLUS

CN L-Phenylalanine, N-[4-[(5-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 167371-72-4P 167371-75-7P 167371-81-5P
 167371-85-9P 167372-10-3P 167372-12-5P
 167372-35-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolo[1,5-a]pyrimidine derivs. angiotensin antagonists)


RN 167371-72-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-ethyl-N-[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 167371-75-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(5-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 167371-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[4-[(5-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl]- (CA INDEX NAME)




RN 167371-85-9 CAPLUS

CN Benzanide, 4-[(5-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N-[2-(2H-tetrazol-5-yl)phenyl]-, hydrochloride (1:?) (CA INDEX NAME)




RN 167372-10-3 CAPLUS

CN Benzenepropanoic acid, α -[4-[(5-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl]- (CA INDEX NAME)




RN 167372-12-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-ethyl-N-[4-(phenyl-2H-tetrazol-5-ylmethyl)phenyl]- (CA INDEX NAME)




RN 167372-35-2 CAPLUS
 CN L-Phenylalanine, N-[4-[(5-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.




L8 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1993:213102 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 118:213102
 ORIGINAL REFERENCE NO.: 118:36739a,36742a
 TITLE: Preparation of pyrazolo[1,5-a]pyrimidine derivatives
 antiinflammatory agents
 INVENTOR(S): Inoue, Makoto; Hashimoto, Kinji; Kuwahara, Toshiko;
 Sugimoto, Yukio; Uesako, Takuji; Funato, Toshiaki
 PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9218504	A1	19921029	WO 1991-JP1043	19910806
W: AU, CA, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2107479	A1	19921023	CA 1991-2107479	19910806
CA 2107479	C	19971216		
AU 9182958	A	19921117	AU 1991-82958	19910806
AU 651986	B2	19940811		
EP 591528	A1	19940413	EP 1991-913666	19910806
EP 591528	B1	19981223		
R: AT, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
AT 174917	T	19990115	AT 1991-913666	19910806
ES 2126573	T3	19990401	ES 1991-913666	19910806
JP 05070353	A	19930323	JP 1992-55370	19920313
US 5688949	A	19971118	US 1993-133086	19931007
PRIORITY APPLN. INFO.:			JP 1991-90707	A 19910422
			WO 1991-JP1043	A 19910806
OTHER SOURCE(S):	MARPAT 118:213102			
GI				




- AB The title compds. [I; R1-R4 = H, CO₂H, Ph, alkoxy carbonyl, alkyl, cycloalkyl, etc.; R1R2 = alkylene; R5 = SR6, NR7R8 (wherein R6 = pyridyl, Ph or substituted Ph; R7, R8 = H, Ph or substituted Ph, etc.)] are prepared A suspension of Cl compound II (R = Cl) 3.5, aniline salt III 6.0, and PhNEt₂ 6.0 in MePh was heated at 120° to give 4.7 g IV, which showed IC₅₀ of 3 × 10⁻⁷M against cyclooxygenase. IV showed 65.0% inhibition against cyclooxygenase at 3 × 10⁻⁷M, vs. 12.4% with indomethacin.
- IT 137739-28-7P 137739-29-9P 137739-36-1P
 137739-31-2P 137739-40-3P 137739-41-4P
 137739-52-7P 137739-53-8P 137739-55-0P
 137739-56-1P 137739-63-6P 137739-65-2P
 137739-67-4P 137739-69-6P 137739-71-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiinflammatory agent)
- RN 137739-28-7 CAPLUS
- CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-(pyrazolo[1,5-a]pyrimidin-7-ylamino)-
 (CA INDEX NAME)




RN 137739-29-8 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[(5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 137739-30-1 CAPLUS

CN Benzoic acid, 2-[(5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, methyl ester (CA INDEX NAME)




RN 137739-31-2 CAPLUS

CN Benzoic acid, 2-hydroxy-5-[(5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, methyl ester (CA INDEX NAME)




RN 137739-40-3 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 137739-41-4 CAPLUS

CN Benzoic acid, 2-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, methyl ester (CA INDEX NAME)




RN 137739-52-7 CAPLUS

CN Benzoic acid, 2-[(5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 137739-53-8 CAPLUS

CN Benzoic acid, 2-hydroxy-5-[(5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-
(CA INDEX NAME)




RN 137739-55-0 CAPLUS

CN Benzoic acid, 2-hydroxy-5-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-
(CA INDEX NAME)




RN 137739-56-1 CAPLUS

CN Benzoic acid, 2-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-,
sodium salt (1:1) (CA INDEX NAME)




RN 137739-63-0 CAPLUS

CN Phenol, 4-[(5-butylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-2,6-bis(1,1-dimethylethyl)- (CA INDEX NAME)




RN 137739-65-2 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[(5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 137739-67-4 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[5-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 137739-69-6 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[(5-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)



RN 137739-71-0 CAPLUS

CN Phenol, 4-[(5-cyclopropylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-2,6-bis(1,1-dimethylethyl)- (CA INDEX NAME)



L8 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:6580 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 116:6580

ORIGINAL REFERENCE NO.: 116:1307a,1310a

TITLE: Preparation of pyrazolo[1,5-a]pyrimidine derivatives as drugs


INVENTOR(S): Inoue, Makoto; Hashimoto, Kinji

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Factory, Inc., Japan

SOURCE: Jpn. Kokai Tokyo Koho, 10 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03204877	A	19910906	JP 1990-289769	19901025
JP 2585462	B2	19970226		

PRIORITY APPLN. INFO.: JP 1989-277566 A1 19891025
 OTHER SOURCE(S): MARPAT 116:6580
 GI




AB The title compds. [I; R1-R4 = H, CO₂H, alkoxy carbonyl, Ph, (HO-, HO₂C-, or alkoxy carbonyl-substituted)alkyl, cycloalkyl; or R1R2 = alkylene; R5 = SR₆, NR₇R₈; R₆ = pyridyl, (1-3 HO- or alkyl-substituted) Ph; R₇, R₈ = H, (1-3 HO-, alkyl-, alkoxy carbonyl-, or HO₂C-substituted) Ph; or NR₇R₈ = 1-pyrrolidinyl, 2-oxo-1-pyrrolidinyl, (un)substituted 1-piperazinyl], useful as antiinflammatories, antirheumatics, antiasthmatics, allergy inhibitors, antipyretics, and analgesics and for improvement of ischemia (no data), are prepared Thus, a suspension of 1.0 g 7-chloropyrazolo[1,5-pyrimidine, 1.8 g 3,5-di-tert-butyl-4-hydroxyaniline-HCl, and 2.3 mL PhNet₂ in PhMe was heated 30 min at 120° to give 890 mg I (R1-R4 = H, R5 = 3,5-di-tert-butyl-4-hydroxyphenylamino). A total of 48 I were prepared

IT 137739-28-7P 137739-29-8P 137739-30-1P
 137739-31-2P 137739-40-3P 137739-41-4P
 137739-52-7P 137739-53-8P 137739-55-0P
 137739-56-1P 137739-63-0P 137739-65-2P
 137739-67-4P 137739-69-6P 137739-71-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as drug)


RN 137739-28-7 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-(pyrazolo[1,5-a]pyrimidin-7-ylamino)-
 (CA INDEX NAME)




RN 137739-29-8 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[(5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 137739-30-1 CAPLUS

CN Benzoic acid, 2-[(5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, methyl ester (CA INDEX NAME)




RN 137739-31-2 CAPLUS

CN Benzoic acid, 2-hydroxy-5-[(5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, methyl ester (CA INDEX NAME)




RN 137739-40-3 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 137739-41-4 CAPLUS

CN Benzoic acid, 2-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, methyl ester (CA INDEX NAME)




RN 137739-52-7 CAPLUS

CN Benzoic acid, 2-[(5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 137739-53-8 CAPLUS

CN Benzoic acid, 2-hydroxy-5-[(5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-
(CA INDEX NAME)




RN 137739-55-0 CAPLUS

CN Benzoic acid, 2-hydroxy-5-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-
(CA INDEX NAME)




RN 137739-56-1 CAPLUS

CN Benzoic acid, 2-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-,
sodium salt (1:1) (CA INDEX NAME)




RN 137739-63-0 CAPLUS

CN Phenol, 4-[(5-butylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-2,6-bis(1,1-dimethylethyl)- (CA INDEX NAME)




RN 137739-65-2 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[(5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)




RN 137739-67-4 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[5-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 137739-69-6 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[(5-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (CA INDEX NAME)



RN 137739-71-0 CAPLUS

CN Phenol, 4-[(5-cyclopropylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-2,6-bis(1,1-dimethylethyl)- (CA INDEX NAME)



=> d his nofil

(FILE 'HOME' ENTERED AT 14:58:57 ON 25 FEB 2009)

FILE 'REGISTRY' ENTERED AT 14:59:03 ON 25 FEB 2009

L1 STR

L2 23 SEA SSS SAM L1

L3 552 SEA SSS FUL L1

FILE 'CAPLUS' ENTERED AT 15:01:30 ON 25 FEB 2009

L4 17 SEA SPE=ON ABB=ON PLU=ON L3

FILE 'WPIX' ENTERED AT 15:01:48 ON 25 FEB 2009

L5 13 SEA SSS SAM L1

L6 99 SEA SSS FUL L1

L7 6 SEA SPE=ON ABB=ON PLU=ON L6/DCR

FILE 'CAPLUS' ENTERED AT 15:02:07 ON 25 FEB 2009

FILE 'CAPLUS' ENTERED AT 15:02:15 ON 25 FEB 2009

 D QUE L4

FILE 'WPIX' ENTERED AT 15:02:19 ON 25 FEB 2009

 D QUE L7

FILE 'CAPLUS, WPIX' ENTERED AT 15:02:24 ON 25 FEB 2009

L8 17 DUP REM L4 L7 (6 DUPLICATES REMOVED)

 ANSWERS '1-17' FROM FILE CAPLUS

 D L8 IBIB ABS HITSTR TOT